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ABSTRACT
Bunyamwera (BUNV), Batai (BATV), and Ngari (NRIV) are mosquito-borne
viruses (Genus: Orthobunyavirus, Family: Peribunyaviridae, Order: Bunyavirales). They
have an RNA tripartite genome consisting of small (S), medium (M), and large (L)
segments. NRIV is a natural reassortant of BUNV and BATV, with the genome: S BUNV,
MBATV, LBUNV. All three viruses have been associated with disease of varying severity in
domestic ruminants and humans. In livestock, infection with these viruses is associated
with abortions, while humans may present a mild febrile illness or severe disease such
as hemorrhagic fever or meningoencephalitis. In East Africa, BUNV, BATV, and NRIV cocirculate and present similar clinical manifestation with Rift Valley Fever virus (RVFV),
another Bunyavirus (Genus: Phlebovirus, Family: Phenuibunyaviridae) of critical
importance in this region as it is associated with massive economic losses in livestock
production and cases of human death. In Rwanda, although RVFV is known to circulate
in livestock, whether these other Bunyaviruses co-circulate remains to be determined.
The overall goal of this research is to describe and compare the in vitro and in
vivo characteristics of BUNV, BATV, and NRIV. To achieve this objective, we a)
comparatively characterized in vitro infection kinetics in Vero cells, b) comparatively
characterized in vivo infection kinetics in C57BL/6 mouse model and quantified potential
cross-neutralization of resulting antibody, and c) developed a disease progression model
for BUNV infection in IRF3/7-/--/- mice. Further, we hypothesized that these
Orthobunyaviruses circulate in Rwanda and cause infections that are misclassified as
RVFV cases. We found: 1) all viruses are stable in extracellular conditions up to 30 days
but inactivation by a commonly used detergent is successful; 2) C57BL/6 mouse infection
xi

is not a robust infection model; 3) there are varying degrees of cross-neutralization among
the viruses; 4) BUNV infection in IRF3/7-/--/- mice may provide hemorrhagic fever infection
model; and 5) these viruses co-circulate with RVFV in Rwanda. This study is the second
report of BATV in Africa, the first to detect these viruses in Rwanda, and the first report
of co-infection with BUNV and BATV, providing insight into the provenance of the
reassortant NRIV.

xii

CHAPTER 1. LITERATURE REVIEW
1.1.

Introduction
The Bunyavirales order, includes more than 350 viruses1 across 10 taxonomic

families namely Hantaviridae, Nairoviridae, Phenuiviridae, Peribunyaviridae, Cruliviridae,
Fimoviridae, Mypoviridae, Wupedeviridae, Phasmaviridae, and Arenaviridae (Maes et al.
2019). Members of this order are often transmitted by mosquitoes and have been
attributed to sometimes severe diseases in humans, livestock, wildlife, and plants
worldwide for a long time (Bishop et al. 1980; Calisher 1996; Elliott 2013). Although
bunyaviral disease manifestation differs among virus species and affected hosts, the most
commonly detected disease is spontaneous abortion in animals (mostly domestic
ruminants) while in humans, infections are generally characterized by non-specific febrile
illnesses though severe forms can manifest with hemorrhagic fever or neurological
complications (Soldan and González-Scarano 2014; Wilson et al. 2015). As these viruses
affect both humans and animals, they are of One Health importance and should be
studied in the context of their multi-factorial impacts in the affected region (s).
Bunyaviruses have single-stranded RNA genome, which is bi-segmented in the
Arenaviridae family (Small and Large segments) and tri-segmented in other families
(Small, Medium, and Large segments). In the Arenaviridae family, the Small segment (S)
encodes major structural proteins (nucleoprotein and glycoproteins) while the Large
segment encodes RNA-dependent RNA polymerase and a Zinc-binding protein (Z)

This chapter has been published as: Dutuze, M. F., M. Nzayirambaho, C. N. Mores, and
R. C. Christofferson. 2018. "A Review of Bunyamwera, Batai, and Ngari Viruses:
Understudied Orthobunyaviruses With Potential One Health Implications." Front Vet Sci
5:69. doi: 10.3389/fvets.2018.00069.
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(Lukashevich 2006; Loureiro, D'Antuono, and López 2019; Vogel et al. 2019). For all other
families, Small (S), Medium (M), and Large (L) segments encode respectively the
nucleoprotein, glycoproteins, and RNA-dependent RNA polymerase. Additionally, S and
M segments of the Peribunyaviridae and Phenuiviridae families encode additional nonstructural proteins (Calisher 1996; Elliott 2013; Soldan and González-Scarano 2014). The
genome of Bunyaviruses is prone to various types of mutations and reassortments, which
can result in altered phenotypic characteristics compared to parental viruses, such as
differences in pathogenesis and even host range (Kolakofsky and Hacker 1991; Elliott
2013; Soldan and González-Scarano 2014; Otieno 2015). This further enhances the one
health implications of these viruses, which are already economically and medically
important due to their significant number, the wide host range, the broad geographic
distribution, and the potentially serious clinical manifestations.
While reassortment among viruses of the Bunyavirales order has been well
documented in experimental settings (Borucki et al. 1999; Briese, Calisher, and Higgs
2013) and predicted to occur at relatively high rates in nature (Briese, Calisher, and Higgs
2013), few recognized natural reassortment events are reported (Bowen et al. 2001;
Briese et al. 2006; Aguilar et al. 2011; Veldhuis et al. 2013; Hontz et al. 2015).
In the Peribunyaviridae family, the largest family of the order, several sudden
discoveries of new viruses have highlighted the importance of reassortment in this group
of viruses. Examples include the identification of the now confirmed reassortant NRIV
and yet to be confirmed but suspected reassortants such as Itaya, Iquitos, and
Schmallenberg viruses (Bowen et al. 2001; Briese et al. 2006; Aguilar et al. 2011;
Veldhuis et al. 2013; Hontz et al. 2015). NRIV has been associated with human
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hemorrhagic fever cases in East Africa in 1998-1999 and with abortive disease in goats
in Mauritania in 2010, cementing its place as a One Health threat (Bowen et al. 2001;
Briese et al. 2006; Beer, Conraths, and van der Poel 2013; Eiden et al. 2014). Itaya virus
is suspected to be a reassortant between Caraparu virus (S and L segments) and another
unknown Orthobunyavirus (M segment) and was associated with human febrile illnesses
between 1999 and 2006 in Peru (Hontz et al. 2015). Iquitos virus was identified as a
reassortant between Oropouche virus (OROV) (S and L segments) and another unknown
Orthobunyavirus (M segment) and associated with febrile illnesses between 2005 and
2006 in Peru (Aguilar et al. 2011). Schmallenberg virus (SBV) is identified as a reassortant
between Shamonda virus (S and L segments) and possibly Sathuperi or Douglas viruses
(for M segment) and has caused severe outbreaks of malformations in ruminants in
several countries of Northern Europe between 2011 and 2012 (Garigliany et al. 2012;
Beer, Conraths, and van der Poel 2013, Yanase et al. 2012; Veldhuis et al. 2013; Wernike
et al. 2014).
Among those viruses produced by natural reassortment events, confidence into the
genetic origins of NRIV is relatively high. Additionally, NRIV could be the reassortant with
highest potential to become a major One Health issue, as it has been found to cause
disease in both humans and animals like its genetic “parents”, sometimes severe (Bowen
et al. 2001; Gerrard et al. 2004; Eiden et al. 2014). Its importance also lies in its broad
range as it has been identified several times in different ecological zones (discussed
further in this chapter), potentially indicative of a broader host or vector range (Zeller et
al. 1996; Gerrard et al. 2004; Aguilar et al. 2011).
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NRIV has been associated with highest pathogenicity among the three viruses: NRIV,
BUNV, and BATV (Zeller et al. 1996; Bowen et al. 2001; Briese et al. 2006; Eiden et al.
2014). The disease associated with BUNV is characterized by mild symptoms such as
fever, joint pain, and rash in many mammals, including humans (Kokernot et al. 1958;
Ashford 2001; Rodrigues Hoffmann et al. 2013; Odhiambo, Venter, Limbaso, et al. 2014;
Tauro et al. 2015). BATV causes a mild flu-like illness in humans but it is associated with
a more severe disease in ruminants where it is manifested by abortions, premature births,
and genetic defects (Ashford 2001; Yanase et al. 2006; Medlock, Snow, and Leach 2007).
NRIV has been associated with fatal hemorrhagic fevers in both humans and ruminants
(Bowen et al. 2001; Briese et al. 2006; Beer, Conraths, and van der Poel 2013; Jackel et
al. 2013; Eiden et al. 2014). However, these reports represent only a handful of actual
isolations and definitive diagnoses and thus, there remains a need to further characterize
these viruses, the diseases they cause, and their potential to become public health
issues, with emphasis on their One Health importance.
BUNV, because it is the most characterized member of the Bunyavirales order, is
known as the prototype of that order (Szemiel, Failloux, and Elliott 2012; Riblett and Doms
2016). BATV has also been studied given its wide distribution across Europe and Asia,
while NRIV is the least studied of the three (Briese et al. 2006; Medlock, Snow, and Leach
2007). Studies of NRIV have been focused on genomic comparisons with other viruses
of the Peribunyaviridae family (BUNV, BATV, and Ilesha viruses) and the similarity of its
clinical manifestations with RVFV (Gerrard et al. 2004; Briese et al. 2006). RVFV is often
associated with abortions in ruminants (cattle, goats and sheep) and mild (flu-like) to
severe (hemorrhagic fever, encephalitis, and ocular troubles) symptoms in humans and
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ruminants. RVFV causes large outbreaks on the African continent and Arabian Peninsula
and is a major public health and food security concern and is a good example of the One
Health paradigm (Balkhy and Memish 2003; Kifaro et al. 2014; Nanyingi et al. 2015; Bird
and McElroy 2016).
The concept of One Health centers on the idea that the health of humans is intimately
tied to the health of animals and the environment (Oura 2014; Asokan 2015; Stadtlander
2015; Mwangi, de Figueiredo, and Criscitiello 2016; Sukura and Hanninen 2016;
Havigerova, Dosedlova, and Buresova 2019). In the case of mosquito-borne viruses,
such as RVFV and the Orthobunyaviruses of concern here, this concept is easily
illustrated by Figure 1.1. Briefly, in developing nations, cattle are often important for food
security, personal and familial economy (Schneider 1957; Hall 1986; Barrett 1992). Thus,
their health is intimately tied to the well-being of the humans associated with those
populations. Further, in zoonotic systems, where viruses may infect both humans and
animals, these cattle may serve as reservoirs or amplification hosts, directly contributing
to the risk of human disease. Finally, the vectors that transmit these viruses are closely
tied to the ecology and environment of the transmission system. Thus, an environmental
component can drive and alter transmission and disease risk in both the human and
animal populations. This system is a One Health system.

5

Figure 1.1. Rift Valley Fever epidemic cycle indicating One Health implications. This cycle
is applicable to other mosquito-borne zoonotic diseases (modified from (Bird and McElroy
2016)).
NRIV was recognized among etiologies of febrile illnesses in humans in various
countries in East Africa. It was identified in Sudan, Somalia, and Kenya outbreaks in 1988,
1997, and 1998, respectively. In these instances, molecular-based techniques such as
nucleic acid amplification and sequencing were rarely used, and diagnosis was based on
clinical manifestations, thus the disease was diagnosed as the most common febrile
illnesses (Nashed, Olson, and el-Tigani 1993; Bowen et al. 2001; Briese et al. 2006;
Groseth et al. 2012). Consequently, in the Sudanese outbreak, the disease was
improperly diagnosed as malaria, as in malaria-endemic countries 70% of febrile illnesses
are treated as presumptive malaria, often without proper medical examination and a
laboratory analysis (Amexo et al. 2004). In Somalia and Kenya, as it was during an
ongoing RVFV outbreak, the disease was mistakenly taken for RVFV. In addition to East
Africa, NRIV has also been identified in goats during an ongoing RVF outbreak in
Mauritania as well (Eiden et al. 2014). This shows that the burden of disease of NRIV and
6

likely BUNV and BATV as well is underreported and their public health impact underappreciated.
In East Africa, despite various isolations of different Bunyaviruses, the status of
many countries in that region remains unknown and requires more investigation. In
Rwanda for example, no extensive research has been conducted on potential presence
of different members of the Bunyavirales order. Although the environment seems suitable
for the transmission of these viruses, the only recognized and surveilled Bunyavirus is
RVFV.
In this literature review, we compile the available knowledge on BUNV, BATV,
and NRIV. Emphasis is put on the relationships among molecular characteristics,
transmission mechanisms, geographic distributions, and clinical manifestations among
the BUNV, BATV, and NRIV, as well as with other related viruses. In addition, we discuss
the documented and potential co-circulation of BUNV, BATV, and NRIV with RVFV, in
East Africa and in Rwanda particularly.

1.2.

Bunyavirales order
The new Bunyavirales order (according to latest taxonomy as of October 2018) is

one of the largest groups of RNA viruses. It counts more than 350 viruses, usually referred
to as ‘Bunyaviruses’ and classified within 10 families. Among the ten (10) families: four
consist old genera of the former Bunyarividae family considered now as families, five
consist of the newly characterized Bunyaviruses, and viruses belonging to Arenaviridae
family joined this order. The members of the former Bunyaviridae family are: former
Hantavirus genus, currently named Hantaviridae family; former Nairovirus genus,
currently named Nairoviridae family; former Phlebovirus genus, currently named
7

Phenuiviridae family for the former, and former Orthobunyavirus genus, currently named
Peribunyaviridae family. The fifth genus of the former Bunyaviridae family-Tospovirus
genus-was moved to Peribunyaviridae family. The five families consisting the newly
characterized Bunyaviruses are Cruliviridae, Fimoviridae, Mypoviridae, Wupedeviridae,
and Phasmaviridae families (Maes et al. 2019).
The taxonomy of these viruses is a dynamic process due to their significant high
number, reassortment events leading to new viruses, widespread distribution, wide host
range, and mostly the non-specific aspect of their diseases.
Except Arenaviridae family which has a bipartite RNA genome, other families of
the Bunyavirales order have tripartite RNA genome consisting of small(S), medium (M),
and large (L) segments due to their relative sizes which are respectively of 961bp-2,916
bp; 3,616-4,888 bp; and 6,404-12,255 bp (Calisher 1996; Soldan and González-Scarano
2014) (Figure 1.1). These RNA segments are single-stranded, exist in helical formation
within the virion, and exhibit a pseudo-circular structure due to each segment’s
complementary end. The L and M segments are negative sense. L encodes the RNA
dependent RNA-polymerase, necessary for viral RNA replication and mRNA synthesis.
The M segment encodes the viral glycoproteins, which projects from viral surface and
help the virus in attaching to and entering the host cell. Additionally, M segment of
members of Peribunyaviridae and Phenuiviridae families encodes NSm is thought to play
a role in virus assembly and suppression of virus-induced apoptosis (Calisher 1996;
Schmaljohn 2001; Soldan and González-Scarano 2014; Otieno 2015). The S segment
encodes nucleocapsid (N) in negative sense. For Peribunyaviridae and Phenuiviridae
families, this segment encodes an additional protein; nonstructural protein (NSs) in
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ambisense (Phenuiviridae) and through overlapping reading frame (Peribunyaviridae)
(Soldan and González-Scarano 2014). NSs has been shown to play an important role in
countering the innate immune response to viral infection, serving as a suppressor of RNA
silencing and inhibiting host cell protein synthesis (Bridgen et al. 2001; Weber et al. 2002;
Soldan et al. 2005). For the Arenaviridae family, the two RNA genome segments S (3.4kb)
and L (7 kb) are all ambisense. The S segment encodes the viral nucleocapsid protein
(NP) and glycoprotein precursor (GPC) which is post-translationally cleaved into Gc and
Gn. L segment encodes Z protein, which binds zinc and acts as a matrix protein, and the
L protein, which is likely to function as the viral polymerase (Figure 1.2) (Hass et al. 2004).

9

Figure 1.2. Bunyavirales genome. A. Genome of Bunyamwera virus (prototype of the Bunyavirales order), representative
of Hantaviridae, Nairoviridae, Peribunyaviridae, Phenuiviridae, Cruliviridae, Fimoviridae, Mypoviridae, Wuperiviridae, and
Phasmaviridae families (Bioinformatics Swiss Institute, 2010a), B. Lassa virus genome, representative of the Arenaviridae
family (Bioinformatics Swiss Institute, 2010b).
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Bunyaviruses are distributed worldwide and cause diseases in a large number of
hosts including humans, livestock, and wildlife. The clinical manifestations of diseases
associated with these viruses vary but are mainly characterized by abortions in livestock,
and mild febrile illness to severe hemorrhagic fever in humans. However, a big proportion
of infections are asymptomatic (Calisher 1996; Elliott 2013; Soldan and GonzálezScarano 2014; Wilson et al. 2015).
The Bunyavirales order includes highly pathogenic viruses of significant public
health concern such as Crimean-Congo hemorrhagic fever virus (CCHFV) in the
Nairoviridae family; Rift Valley fever virus (RVFV), Severe fever with thrombocytopenia
syndrome virus (SFTSV), and Toscana virus (TOSV) in the Phenuiviridae family; La
Crosse virus (LACV), Oropouche virus (OROV), Cache Valley virus (CVV), and Akabane
virus (AKAV) in the Peribunyaviridae family; as well as Lassa virus (LASV) in the
Arenaviridae family. These viruses are causative of severe and fatal illnesses
characterized by hemorrhagic fever, pulmonary disease, congenital abnormalities, and
encephalitis (Zeller et al. 1996; Zentis et al. 2012; Soldan and González-Scarano 2014;
McDonald et al. 2016; Dutuze et al. 2018).
With exception of the members of the Hantaviridae family which are rodenttransmitted, Bunyaviruses are principally transmitted by arthropods. Unlike most
arboviruses which tend to be adapted to a narrow range of vectors, arthropod-borne
Bunyaviruses are transmitted by a wide range of vectors such as mosquitoes, ticks, flies,
sandflies, and biting midges (Calisher 1996; Wertheim 2012; Elliott 2013).
In addition, direct transmission is an important way of transmission in cases of
hemorrhagic fever and abortions when the virus is largely being spread in the
11

environment. This has been found to be significantly important in transmission of RVFV,
and CCHFV (Shepherd et al. 1989; Balkhy and Memish 2003; Conger et al. 2015;
Pshenichnaya and Nenadskaya 2015; Bird and McElroy 2016).
Like for all RNA viruses, Bunyaviruses are subjects to various mutations (Elliott 1989a;
Weber and Elliott 2002). Additionally, the segmented structure of their genome exposes
them to reassortment, a process of genetic recombination exclusive to segmented RNA
viruses in which co-infection of a host cell with multiple viruses may result in the shuffling
of gene segments to generate progeny viruses with novel genome combinations (Weber
and Elliott 2002). Theoretically, co-infection of two tri-segmented Bunyaviruses would
lead to the creation of 6 (23-2) reassortants while co-infection of bi-segmented
Bunyaviruses would lead to 2 (22-2) reassortants. However, this process requires genetic
compatibility between parental viruses, which occurs in the form of conserved packaging
signals, maintenance of RNA, and protein interactions (McDonald et al. 2016). This may
explain why even though many Bunyaviruses co-circulate in the same regions and share
hosts and vectors, reassortment events are not as many as the theory seems to indicate.
Reassortment may result in novel aspects of pathogenesis, pathogenicity, and virulence
within same hosts. This has been seen with the unusually high pathogenicity of NRIV in
humans and SBV in ruminants (Bowen et al. 2001; Briese et al. 2006; Garigliany et al.
2012; Yanase et al. 2012; Beer, Conraths, and van der Poel 2013; Wernike et al. 2014).
Due to the significant number of members in this order and to the non-specific disease
manifestations, these reassortments are thought to go unnoticed except when they are
clinically manifested with severe alarming signs (Briese, Calisher, and Higgs 2013).
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One of the most documented naturally occurring reassortement is the creation of
Ngari virus (NRIV) from Bunyamwera virus (BUNV) and Batai virus (BATV), two members
of Orthobunyavirus in the Peribunyaviridae family. The three viruses cause diseases in
animals and humans and are characterized by different virulence. BUNV is characterized
by moderate virulence, BATV by low virulence while NRIV is more virulent than its two
“parents” (Bowen et al. 2001; Briese et al. 2006; Medlock, Snow, and Leach 2007;
Rodrigues Hoffmann et al. 2013; Eiden et al. 2014; Tauro et al. 2015).
Despite their relatively significant medical importance, their presumably related
geographic distribution, and the less-characterized conditions of this natural
reassortment, these viruses are understudied. This dissertation covers the comparative
characterization of BUNV, BATV, and NRIV on different aspects such as in vitro and in
vivo infection kinetics, geographic distribution, and (dis) similarities with RVFV especially
on clinical manifestation.
1.3.

Bunyamwera, Batai, and Ngari viruses

1.3.1. Origins and geographic distributions
BUNV was first isolated in 1943 from Aedes mosquitoes collected in the Semliki Forest
of Uganda as part of a yellow fever surveillance effort (Smithburn, Haddow, and Mahaffy
1946; Kokernot et al. 1958; Szemiel, Failloux, and Elliott 2012). BUNV is now considered
endemic in several African countries, such as Uganda, Tanzania, Mozambique, Nigeria,
Guinea, South Africa, and Democratic Republic of Congo (Figure 1.2). Recently, Cache
Valley Fever virus was classified as a strain of BUNV, which expands its geographic range
to the North and strains of BUNV were isolated in Argentina (Tauro et al. 2015). A recent
compilation of studies reported the presence of BUNV in Senegal, Guinea, Ivory Coast,
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Nigeria, Cameroon, Central African Republic, Kenya, Uganda, South Africa, and
Madagascar (Wertheim 2012).
Ngari virus was first isolated from Aedes simpsoni mosquitoes in 1979 in Southeastern
Senegal. It was then recovered from several mosquito species in Senegal, Burkina Faso,
Central African Republic and Madagascar (1988–1993) (Zeller et al. 1996). The first
suspicion of its potential pathogenicity in humans was when the virus was isolated from
two patients in Dakar in October and November 1993 (Wertheim 2012). In Kenya and
Somalia (1998–1999), the Garissa strain of NRIV was identified in what was thought to
be a RVFV outbreak, owing to the hemorrhagic manifestations of infection (Bowen et al.
2001). In 2010, during an ongoing RVFV outbreak in Mauritania, NRIV was again isolated
in goats (Eiden et al. 2014). NRIV has additionally been isolated in Burkina Faso, Central
African Republic, and Madagascar (Wertheim 2012). In all these cases, microscopy, RTPCR, and complete nucleotide sequences were used in the differential diagnostic panels
and confirmed the differentiation between other Bunyaviruses (BUNV, BATV, ILEV, and
RVFV) as well as other suspected agents (malaria) (Bowen et al. 2001; Gerrard et al.
2004; Eiden et al. 2014).
Batai virus is one of the most geographically widespread members of the
Orthobunyavirus genus (Figure 1.3) (Briese et al. 2006; Groseth et al. 2012). It also has
the broadest vector range as it was isolated from Anopheles maculipennis in
Czechoslovakia in 1950, from Culex gelidus Theo mosquitoes in Malaysia, from
Anopheles barbirostris mosquitoes in the Chittoor district in India, and from A.
maculipennis and Aedes punctor mosquitoes collected in what is modern Ukraine (Singh
1966; Gaidamovich et al. 1973; Karabatsos 1985; Briese et al. 2006; Szemiel, Failloux,

14

and Elliott 2012; Liu et al. 2014). In Europe, evidence for circulation exists in Norway,
Sweden, Finland, Slovakia, the Czech Republic, Croatia, Serbia, Bosnia, Montenegro,
Italy, Hungary, Romania, Austria, Portugal, Germany, and Belarus (Hubálek 1996). The
seroprevalence reported in humans in Europe is low: less than 1% in Sweden, Finland,
Germany, Austria, and parts of the former Yugoslavia. However, there was a 32%
seroprevalence reported in southern Slovakia (Medlock, Snow, and Leach 2007).
Similarly, seroprevalence in animals varied from 1 to 46% (Medlock, Snow, and Leach
2007). Interestingly, BATV is not widely reported on the African continent, having only
been reported in Uganda in 1967 based on molecular techniques (PCR) (Briese et al.
2006) and highly suspected in Sudan in 1988 based on serological technique (PRNT)
(Nashed, Olson, and el-Tigani 1993). However, the distribution of NRIV as well as the
presence of suitable hosts and vectors suggests that BATV might be present in other
African countries and be underreported, or at least has the potential to be so.
Although no research has been conducted on the asymptomatic presentation of
BUNV, BATV, and NRIV infections in vertebrate hosts, other mosquito-borne viruses
across several genera are known to present as mostly asymptomatic or as a mild
influenza- like illness (Hollidge, González-Scarano, and Soldan 2010). Therefore, it is
possible that NRIV, BUNV, and even BATV were circulating before successful isolation
and that they may silently circulate in many areas, where no serological studies have
been conducted that may detect asymptomatic or mild, generalized disease.
NRIV was isolated 35 years ago, nearly 30 years after the parental viruses, BUNV
and BATV. Given the geographical history of BUNV and BATV, the speculation is that the
first reassortment leading to new viral progeny likely resulted from the introduction of
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BATV into the population of already-circulating BUNV in Africa. Many factors may have
contributed to the introduction of BATV in East Africa, likely long-distance bird migration
(Altizer, Bartel, and Han 2011). But these distinct geographies of BATV and BUNV also
suggest that NRIV likely has developed its own niche and propagates as a distinct virus
rather than relying on repeated introductions and chance co-infections of BATV and
BUNV in the wild.

Figure 1.3. Geographic distribution of BUNV, BATV, and NRIV (1943-2015). The known
distributions of Bunyamwera, Ngari, and Batai viruses in Europe and Africa, where most
isolations have occurred. Not shown are periodic isolations in Russia, India, Malaysia,
and China, as well as Cache Valley Fever Virus in North America.
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1.3.2. Classification, genomic characteristics and replication in host cells
a. Classification
BUNV, BATV, and NRIV belong to the Bunyamwera group, one of 18 serologically
defined arbovirus serogroups belonging to the Orthobunyavirus genus of the family
Peribunyaviridae (Yanase et al. 2006). The 18 serogroups are Anopheles A, Anopheles
B, Bakau, Bunyamwera, Bwamba, group C, Capim, California, Gamboa, Guama,
Koongol, Minatitlan, Nyando, Olifanstlei, Patois, Simbu, Tete, and Turlock (Mohamed,
MacLees, and Elliott 2009). The viruses of this genus have been classified into these
different serogroups based on serological relationships of complement fixing antibodies,
as well as hemagglutinating assay results and neutralizing antibodies (Calisher 1996).
The classification of the Bunyaviridae family has evolved, since its first organization in
1971 when the Subcommittee on Interrelationships Among Catalogued Arboviruses
(SIRACA) conducted a serological study of 23 viruses. They subsequently classified 14
viruses as belonging to the Bunyamwera group viruses and further identified five
subgroups or complexes: Bunyamwera, Cache Valley, Wyeomyia, Kairi, and Guaroa
(Scherer 1976). In 1978, this classification was updated based on the antigenic
relationships of the Bunyamwera group viruses established by the cross-neutralization
pattern of virus-specific hyperimmune antibodies (Tikasingh, Spence, and Downs 1966).
From this effort emerged three subgroups that diverge largely over geographic origin:
South America, Africa, and Europe/Asia (of which BATV is the only member) (Hunt and
Calisher 1979). While there was very little cross-neutralization among members of the
South-American and African subgroups, BATV is cross-neutralized by other virus-specific
antibodies from the other two subgroups (Hunt and Calisher 1979). As of 1996, there are
over 30 Bunyamwera serogroup viruses that have been identified and classified (Calisher
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1996). As mentioned, CVV was also recently reclassified as a strain of BUNV (Tauro et
al. 2015). Table 1.1 shows the 32 Bunyamwera group viruses and the geographic areas,
where they were first isolated, as well as their main vertebrate hosts and principal vectors.
Most of the Bunyamwera serogroup viruses are etiological agents of human and animal
diseases (Southam and Moore 1951; Kokernot et al. 1958; Causey et al. 1961; Casals
1965; Groseth et al. 2012).
The taxonomy of Bunyaviruses has been challenging, given the propensity for
reassortment, their general lack of characterization, and the broad geographic ranges of
some genera. Often, taxonomy is first developed based on antigenic relationships, but is
becoming more molecular-based as genomic methods become cheaper and data
becomes available (Kuhn et al. 2016). Recently, the International Committee on
Taxonomy of Viruses proposed the latest classification whereby from the family of
Bunyaviridae, a new virus order of Bunyavirales was created. As previously mentioned,
the new Bunyavirales order consists of ten families combining all viruses of the former
Bunyaviridae family, the newly characterized Bunyaviruses, and viruses of the
Arenaviridae family. In this classification, BUNV, BATV, and NRIV belong to
Orthobunyavirus genus of the Peribunyaviridae family (Maes et al. 2019).
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Table 1.1. The 32 viruses of the Bunyamwera group, geographic areas of origin, main hosts, and principal vectors, including
relevant references
Virus

Abbreviation

Source, location, year of

Main hosts

first isolation
AG83 1746
Anhembi

AM

Principal

arthropod

References

vectors

South America

Rodents

Mosquitoes

(Calisher 1996)

Brasil

Not known

Mosquitoes (culicine)

(Hunt and Calisher 1979; Calisher
1996)

Batai

BAT

BeAr

Anopheles maculipennis,

Humans,

Mosquitoes

(Hunt and Calisher 1979; Calisher

Czechoslovakia, 1950

ruminants, sentinel

(anopheline, culicine),

1996; Liu et al. 2014)

animals (birds)

Biting midges

South America

Not known

Mosquitoes

(Calisher 1996)

Anopheles

Not known

Mosquitoes

(Hunt and Calisher 1979; Calisher

(anopheline)

1996; Liu et al. 2014)

Mosquitoes

(Calisher 1996)

3282208
Birao

BIR

pharoensis,

Central Afr. Rep., 1969
Bozo

Africa

Not known

(anopheline, culicine)
Bunyamwera

BUN

Aedes spp., Uganda,

Humans

1943
Cache valley

(Hunt and Calisher 1979; Calisher

(anopheline, culicine)

1996; Liu et al. 2014)

Culiseta inornata, Utah,

Sheep, cattle,

Mosquitoes

(Hunt and Calisher 1979; Calisher

1956

marsupials

(anopheline, culicine)

1996; Liu et al. 2014)

CbaAr426

South America

Not known

Mosquitoes

(Calisher 1996)

Fort Sherman

Human, Panama, 1985

Humans

Mosquitoes

(Calisher 1996; Liu et al. 2014)

South Africa

Humans, rodents,

Mosquitoes (culicine)

(Hunt and Calisher 1979; Calisher

Germiston

CV

Mosquitoes

GER

sentinel animals

(Table 1.1 cont’d)
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1996)

Virus

Abbreviation

Source, location, year of

Main hosts

first isolation
Guaroa

GRO

Iaco
Ilesha

ILE

Principal arthropod

References

vectors

Colombia

Humans

Mosquitoes

(Hunt and Calisher 1979)

South America

Not known

Mosquitoes (culicine)

(Calisher 1996)

Human, Nigeria, 1957

Humans

Mosquitoes (anopheline)

(Hunt and Calisher 1979; Liu et al.
2014)

Kairi

KRI

Trinidad

Equine, primates,

Mosquitoes (culicine)

(Calisher 1996)

Cattle, goats,

Mosquitoes (anopheline,

(Hunt and Calisher 1979; Calisher

sheep

culicine), Culicoid flies

1996,)

South America

Rodents, bats

Mosquitoes (culicine)

(Calisher 1996)

Aedes scapularis,

Sentinel animal,

Mosquitoes (anopheline,

(Hunt and Calisher 1979; Calisher

Ecuador, 1974

cattle

culicine)

1996; Liu et al. 2014)

USA

Equine

Mosquitoes (culicine),

(Hunt and Calisher 1979; Calisher

Culicoid flies

1996)

rodents, sentinel
animals
Lokern

LOK

Macaua
Maguari

Main Drain

MAG

MD

USA

Mboke

Africa

Not known

Mosquitoes (culicine)

(Calisher 1996)

Ngari

Aedes simpsoni,

Humans

Mosquitoes (anopheline,

(Calisher 1996; Odhiambo, Venter,

culicine), ticks

Chepkorir, et al. 2014; Odhiambo

Senegal, 1979

et al. 2015)
Northway

NOR

Aedes spp., Alaska,

Rodents, sentinel

Mosquitoes (culicine)

(Hunt and Calisher 1979; Liu et al.

1971

animals

Playas

South America

Not known

Mosquitoes (culicine)

(Elliott 1997)

Potosi

Aedes albopictus,

Not known

Mosquitoes

(Elliott 1997; Liu et al. 2014)

2014)

Missouri,1989

(Table 1.1 cont’d)
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Virus

Abbreviation

Source, location, year of

Main hosts

first isolation

Principal arthropod

References

vectors

Santa Rosa

North America

Not known

Mosquitoes (culicine)

(Hunt and Calisher 1979)

Shokwe

Aedes cumminsii, South

Humans, rodents

Mosquitoes (anopheline,

(Hunt and Calisher 1979; Calisher

culicine)

1996; Liu et al. 2014)

Mosquitoes (culicine)

(Hunt and Calisher 1979; Calisher

Africa, 1962
Sororoka

SOR

Brazil

Not known

1996)
Tensaw

Tlacotalpan

TEN

TLA

USA

Mexico

Rodents, sentinel

Mosquitoes (anopheline,

animals, cattle

culicine)

Not known

Mosquitoes

(Calisher 1996)

(Hunt and Calisher 1979; Calisher
1996)

Tucunduba

Brazil

Not known

Mosquitoes

(Hunt and Calisher 1979; Calisher
1996)

Wyeomyia

WYO

Wyeomyia

Not known

melanocephala,

Mosquitoes (anopheline,

(Hunt and Calisher 1979; Calisher

culicine)

1996: Liu et al. 2014)

Mosquitoes

(Elliott 1997; Liu et al. 2014)

Colombia, 1940
Xingu

Human, Brazil, unknown

Humans

date
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b. Genomic characteristics
As with all viruses in the Peribunyaviridae family, BUNV which is the prototype of
the family has a segmented negative sense RNA genome. As stated, the genome is
composed of three segments S, M, and L. Each segment is transcribed individually to
give a single mRNA (Figure 1.4). Although there are differences in the sizes of the
segments among different species and among strains within species, the averages for
Orthobunyaviruses are 6.9 kb for the L segment, 4.5 kb for the M segment and 1.0 kb for
the S segment (Elliott 2014). The S segment encodes the N (nucleocapsid) protein and
a NSs, which are translated from overlapping open reading frame in the same mRNA by
leaky ribosomal scanning (Fuller and Bishop 1982; Beaty, Fuller, and Bishop 1983; Elliott
1989b; Elliott 2014). The M segment mRNA encodes a polyprotein that is posttranslationally cleaved by host proteases into NS, and glycoproteins (Gn and Gc)
(Gentsch and Bishop 1979; Fuller and Bishop 1982; Elliott 1985) and the L segment
mRNA encodes the RNA-dependent RNA polymerase (Elliott 1989b; Walter and Barr
2010; Elliott 2014) (Figure 1.4). As in other Bunyavirus families (Nairoviridae and
Phenuiviridae), NSs and NSm have been shown to be closely related to the pathogenicity
and propagation of the viruses in vertebrate cells (Kuhn et al. 2016; Phoenix et al. 2016).
Although NSs is encoded by all three viruses, the length of this gene can vary among the
genus (Elliott 2014).
The coding sequences are generally less conserved than the untranslated regions
(UTRs). The functional promoter is formed by the 5′ and 3′ UTRs of each segment
(Barr et al. 2003; Kohl et al. 2004; Barr and Wertz 2005; Elliott 2014). 3′ and 5′ UTRs
are complementary. The deletion of internal sequences in the UTRs of BUNV resulted in
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attenuation of virus replication and loss of cytopathogenicity in mammalian cell culture,
but the mechanistic basis of this remains unclear [91, 102].

Figure 1.4. Genomic organization of BUNV, BATV, and NRIV. NRIV takes the L and S
segments from BUNV and the M segment from BATV. The M segment transcripts are
translated into a polyprotein which is split into Gn, NSm and Gc after post-translational
modifications. Nucleotide lengths were taken from specific strains (GenBank accession
numbers: NC_001925, NC_001926, NC_001927, JX846597, JX846596, JX846595,
KC608152, KC608153 and KC608154 for BUNV-L segment, BUNV- M segment, BUNVS segment, BATV-L segment, BATV-M segment, BATV-S segment, NRIV-L segment,
NRIV M segment and NRIV-S segment respectively). ORF: open reading frame, UTR:
untranslated region, NSs: non-structural protein encoded by the S segment, NSm: nonstructural protein encoded by the M segment, Gc and Gn: glycoproteins, nt; nucleotides.
Like other Orthobunyaviruses, Bunyamwera serogroup viruses are able to increase
genetic and phenotypic diversity through reassortment of genome segments during mixed
infections with viruses of the same group (Borucki et al. 1999; van Knippenberg and Elliott
2015). For example, reassortment between Bunyamwera, Maguari, Batai, and Northway
viruses were obtained in cell cultures (Weber et al. 2002). NRIV is a naturally occurring
reassortment resulting from a BUNV and BATV co-infection, though it is unknown whether
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this co-infection was in the vector or a vertebrate host (Zeller et al. 1996; Gerrard et al.
2004). The L and S segments of NRIV are from BUNV and the M segment from BATV
(SBUNV, MBATV, LBUNV) (Zeller et al. 1996). There are 93%, 97–98%, and 89–95%
nucleotide sequence homologies between BUNV and NRIV S segments; BUNV and
NRIV L segments; and between BATV and NRIV M segments respectively (Gerrard et al.
2004; Briese et al. 2006). Little is known about the roles of different factors related to the
occurrence of the reassortment events, such as host species, viral titers, and viral strains.
Indeed, the lack of understanding of the genomic variability of these viruses, especially
NRIV, means that we are unable to entirely understand the phylogenetic relationships
among species and strains of species, and thus we cannot fully appreciate the processes
that promote reassortment and the extent of propagation of such strains. Similar
challenges exist for related Bunyaviruses, such as Nairovirus, and recent efforts have
established new species and that there is some plasticity to classification of Bunyaviruses
related in large part to the lack of comprehensive sequence data (Elliott 2014).
c. Replication in Host Cells
Bunyaviridae are enveloped viruses that replicate in the cytoplasm of mammalian
cells and bud into the Golgi apparatus (Elliott 1985; Weber et al. 2002). Host cell entrance
is by clathrin-dependent endocytosis and vacuolar acidification, though the receptors,
cellular factors, and specific pathways are not well understood (Jin et al. 2002; Simon,
Johansson, and Mirazimi 2009; Odhiambo, Venter, Limbaso, et al. 2014). The two
envelope glycoproteins Gc and Gn are responsible for viral attachment and acid-activated
penetration (Albornoz et al. 2016). It has been reported that the entry of Germiston and
LaCrosse viruses, two other Orthobunyaviruses, is promoted by DC-SIGN (Dendritic cell-
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specific intracellular adhesion molecule-3-grabbing non-integrin) receptors, which is seen
in other Bunyaviruses, like the Phleboviruses (Phoenix et al. 2016). These receptors are
found in dermal dendritic cells and may play a role in viral entry into mammalian cells
following transmission by an arthropod bite (Albornoz et al. 2016; Phoenix et al. 2016).
As with many arboviruses, in vitro infection is generally lytic in mammalian cell lines, while
these viruses produce a persistent infection in mosquito cells with a lack of cytopathic
effect (Newton, Short, and Dalgarno 1981; Bird and McElroy 2016). In vitro infection of
Aedes aegypti cells with BUNV revealed that NSs are essential for viral replication, as
these cells were refractory to infection with a recombinant NSs gene deletion strain
(rBUNdelNSs2) (Newton, Short, and Dalgarno 1981; Bird and McElroy 2016). Further
infections of Aedes albopictus cell lines with both a wild-type BUNV and another
recombinant NSs gene deletion strain showed that the wild-type strain demonstrated
greater fitness with 100-fold higher titers (Szemiel, Failloux, and Elliott 2012). In
mammalian cell lines, NSs are also implicated in pathogenesis, as NSs induced shut-off
of host protein synthesis and resulted in cell death (Nashed, Olson, and el-Tigani 1993;
Szemiel, Failloux, and Elliott 2012; Tauro et al. 2015).
Infection of BHK cells first showed cytopathic effect at 3 h post- infection. Using Vero
cells, most BUNV group members produce clear plaques within 4 days (Groseth et al.
2012). BUNV isolates were shown to grow to higher titers than NRIV isolates (Odhiambo,
Venter, Limbaso, et al. 2014). Additionally, after serial passage on Vero cells, NRIV was
found to have total conservation of N and NSs proteins, while nucleotide substitutions
were observed in both the S and M segments of subsequent passages of BUNV, which
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may suggest that the NRIV genome is more stable in Vero cells than its parent BUNV
(Odhiambo, Venter, Limbaso, et al. 2014).
Persistent infection in C6/36 cells is not associated with cytopathic effects and can
last indefinitely. Persistent infection in mammalian cells or long-term infection in
mammalian cells or culture media without cells has been noted in other Bunyaviridae
viruses but has not been reported for Orthobunyaviruses (Elliott 1985, Hardestam et al.
2007).
1.3.3. Transmission and Epidemiology
Bunyamwera virus is likely maintained in nature by blood- feeding mosquitoes and
susceptible vertebrate hosts. Evidence suggests the Ae. aegypti might be the primary
mosquito vector (Odhiambo, Venter, Chepkorir, et al. 2014; Tauro et al. 2015).
Experimental studies showed that Ae. aegypti was competent to transmit BUNV, but not
a competent vector for NRIV. However, Anopheles gambiae Giles was competent for both
viruses, while Culex quinquefasciatus did not demonstrate competence to transmit either
of the two viruses (Odhiambo, Venter, Chepkorir, et al. 2014). The two identified NRIV
outbreaks of human febrile illnesses (Sudan in 1988 and Somalia- Kenya in 1997–1998)
coincided with episodes of unusually heavy rains and extensive flooding in areas normally
arid (Briese et al. 2006). This seasonal emergence pattern resembles that of RVFV, the
primary vector of which is Ae. aegypti (Pepin et al. 2010; Nanyingi et al. 2015).
Ngari virus has been isolated in many mosquito vectors, such as Aedes
argenteopunctatus, Aedes minutus, Aedes vexans, Aedes mcintoshi, Anopheles
coustani, Aedes neoafricanus, Aedes simpsoni, Aedes vittatus, Anopheles pretoriensis,
Anopheles phar-oensis, Anopheles mascarensis, Culex bitaeniorhynchus, Culex tri-
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taeniorhynchus, Culex antennatus, and Culex poicilipes in Senegal during a study period
from 1991–1994 (Zeller et al. 1996). These successful isolations suggest a large vector
range, which could indicate the potential for widespread geographic distributions as well
as potential vertebrate host ranges, given the diversity of feeding preferences of these
mosquitoes.
Batai virus has been isolated from cattle and human patients (Nashed, Olson, and elTigani 1993; Yanase et al. 2006; Liu et al. 2014). BATV has been isolated from several
mosquito species as described above, and additionally in Anopheles claviger,
Coquillettidia richiardii, Culex pipiens s.i., Ochlerotatus punctor, Ochlerotatus Communis,
and Ae. vexans (Francy et al. 1989; Hubálek 2008; Lozach et al. 2010). BATV has also
been shown to be transmitted by biting midges (Culicoides spp.) and ticks (Dilcher et al.
2013).
Because the risk for BATV transmission has been correlated with migratory and
resident bird population distributions, BATV is thought to be associated with bird-mosquito
enzootic cycle similar to WNV, Usutu virus, and Sindbis virus (Hubálek 1996; Lozach et
al. 2010).
Indeed, the migratory patterns of competent bird species likely accounts for its wide
geographic distribution across Europe and Asia (Hubálek 2008, Hofmann et al. 2015).
BATV infection is less severe in humans, though it occurred epidemically in Scandinavia
in the 1960s. In addition, neutralizing antibodies have been detected in cows and one
farmer on coastal farms in Finland (Brummer-Korvenkontio 1973; Brummer-Korvenkontio
and Saikku 1975; Medlock, Snow, and Leach 2007).
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1.3.4. Associated diseases
All three viruses (BUNV, NRIV, and BATV) have been reported to infect humans and
other mammals. BUNV causes mild symptoms in humans, such as fever, headache, joint
pain, and rash. Symptomatic infections are more often reported in children, and
immunocompromised patients may progress to severe encephalitis (Ashford 2001). In
domestic animals, especially ruminants, infection leads to severe symptoms, such as
spontaneous abortion and teratogenic effects (Rodrigues Hoffmann et al. 2013). In 2013,
BUNV was isolated for the first time in horses in Argentina after two horses developed
neurological signs and died (Tauro et al. 2015). CVV is endemic to North America and
causes very severe diseases in humans and ruminants characterized by embryonic and
fetal death, stillbirths, and multiple congenital malformations especially in ruminants.
Humans are rarely infected by CVV, however, severe headache, nausea, vomiting,
fatigue, encephalitis, and multiorgan failure have been reported in patients (Tauro,
Campbell et al. 2006; Almeida, and Contigiani 2009; Armstrong, Andreadis, and
Anderson 2015).
BATV infections in livestock results in abortions, premature births, and congenital
defects (Yanase et al. 2006; Dilcher et al. 2013; Rodrigues Hoffmann et al. 2013). In
humans, BATV infection has been characterized as a non-descript febrile illness in Africa
and Asia and associated with an influenza-like illness in Europe (Lozach et al. 2010).
Febrile disease, bronchopneumonia, exudative pleurisy, catarrhal and follicular tonsillitis,
and acute gastritis have all been reported clinical signs associated with BATV infection in
humans (Sluka 1969; Medlock, Snow, and Leach 2007).
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NRIV is reported to cause severe and fatal hemorrhagic fever (Gerrard et al. 2004).
NRIV clinical manifestations are similar to those of RVFV, as seen in humans in the Kenya
and Somalia outbreaks (1998–1999) and in animals in the Mauritania outbreak (2010)
(Bowen et al. 2001; Jackel et al. 2013). NRIV has also been isolated from small ruminants
with hemorrhagic manifestations (Jackel et al. 2013).
1.3.5. One Health implications
While BATV is less associated with severe human disease, it can lead to significant
economic losses as it infects agriculturally important mammals and bird species (Sluka
1969; Yanase et al. 2006; Medlock, Snow, and Leach 2007; Rodrigues Hoffmann et al.
2013). However, given that RVFV, BUNV, and NRIV present many similarities in their
clinical manifestations, co-circulate within the same vector and/or vertebrate host ranges,
and share the same ecological distribution, NRIV and BUNV might contribute to outbreaks
of hemorrhagic fever in these regions of both cattle and humans. Indeed, there is
evidence for co-circulation in Kenya (1997–1998), where RVFV and NRIV were found in
23 and 27%, respectively of human hemorrhagic fever cases tested, which was the first
report of BUNV causing human disease (Bowen et al. 2001). In Mauritania (2010), during
an ongoing RVFV outbreak in livestock, 163 serum samples (62 from camels, 8 from
cattle, and 93 from small ruminants) were tested for NRIV, where two goat samples were
positive for NRIV (Eiden et al. 2014). In addition, one of these two samples was also IgM
positive for RVFV, suggesting a recent (possibly co-) infection of RVFV (Eiden et al.
2014). These data suggest that in areas, where RVFV is reported but not confirmed or
where the etiologic agent has not been molecularly confirmed, BUNV and NRIV should
be included in a differential diagnostic panel for hemorrhagic fevers of humans and
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animals (Gerrard et al. 2004; Briese et al. 2006). That being said, the diagnostic
capabilities available for Orthobunyaviruses in general are limited. Detection of nucleic
acid has been utilized and is capable of differentiating between BATV, NRIV, and BUNV,
but requires multiple genes to be amplified. Inherent in this method is the assumption that
there are no co-infections of NRIV and one of its parental viruses, as theoretically, a coinfection of BATV and BUNV would give the same PCR read-out as NRIV. Thus,
serological assays are needed to detect circulation of these viruses. Cross-neutralization
among these viruses is not limited to these three, and traditional PRNT methods are likely
to be unable to distinguish to the species level (Hunt and Calisher 1979). In addition, there
is a commercially available nucleotide and antibody bundle that was developed for Cache
Valley Fever virus (Discovery Antibodies, UK), a strain of BUNV, which purports to crossreact with BATV. Thus, while diagnostic capability for these three Orthobunyaviruses
exists, whether or not there is an ability to definitively identify which virus is the agent
remains unclear.
In addition to diagnostic capabilities, there is a better need to understand the control
and prevention of transmission. A first step in this process is identifying the mosquito
vectors of medical and veterinary importance. To that point, the geographic distribution(s)
of these three viruses should be better characterized in effort to accurately assess which
mosquito vectors could transmit. Additionally, comparative vector competence studies
should be conducted in efforts to elucidate the relative transmission potential of these
three viruses. Although BATV is mainly defined as European/Asian virus and has only
once been isolated in Africa, it may be present in several other countries in Africa, but
underreported, since NRIV has only been isolated in Africa and BATV is its presumptive
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parent. After identification of likely vectors, appropriate control methods can be
implemented, such as additional spraying efforts, behavior modification, and education
programs. Since the life cycles of vectors are closely related to climatic conditions, the
role of climate change in continued circulation, the potential for altered and expanded
geographic distributions, and seasonality of transmission should be considered in all
prevention campaigns.
1.4.

Bunyavirus environmental suitability in Rwanda

Although important efforts have been done in inventorying arboviruses circulating in
Rwanda, its status remains less characterized. Different arboviruses such as Flaviviruses
(Yellow Fever virus, Zika virus, West Nile virus, and non-identified Flaviviruses), nonidentified Alphaviruses, and Bunyaviruses (Rift Valley Fever virus) have been found to
circulate in Rwanda (Demanou 2011; Kading et al. 2013; Rwanda Agriculture Board 2013;
Rwanda Ministry of Health 2017; Umuhoza et al. 2017; Seruyange et al. 2018; USAID
2018). In human populations, YFV seroprevalence of 0.16% and ZIKV seroprevalence of
1.4% were reported respectively by PRNT and IgG ELISA (Demanou 2011; Seruyange
et al. 2018). In wildlife, a serosurveillance on Alphaviruses and Flaviviruses conducted in
the Congo basin region (including DRC, Gabon, Chad, Rwanda, and Zambia), using the
PRNT technique, reported that over 17 gorillas from Rwanda, 2 were positive to nonidentified Alphavirus(es), 2 were positive to WNV, and 1 positive to non-identified
Flavivirus (es) (Kading et al. 2013). In livestock, Rift Valley Fever virus is regularly
reported, surveilled, and causes significant economic losses in livestock production
(Umuhoza et al. 2017). Although RVFV is the only Bunyavirus reported in Rwanda,
different factors such as environmental parameters, proximity and important human and
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animal movements between countries such as Kenya and Uganda, where more
Bunyaviruses are regularly reported (Kifaro et al. 2014; Nanyingi et al. 2015; Bird and
McElroy 2016; Dutuze et al. 2018) suggest that Rwanda is exposed to Bunyavirus
transmission.
Rwanda is characterized by temperate tropical climate which is known to be favorable
for mosquito emergence thus making it suitable for bunyaviral and arboviral disease
transmission in general (Loevinsohn 1994). There are four weather seasons in Rwanda:
moderate dry season (December-February), intense rainy season (March-May), intense
dry season (June-September), and moderate rainy season (October-November).
Geographically, based on rainfall, vegetation, and altitude, Rwanda is divided into 4
ecological zones with the following characteristics (Demanou 2011) (Figure 1.5).
Zone 1. Forested, high level of precipitation, altitude <2,300 m;
Zone 2. Forested, high level of precipitation, altitude >2,300 m in few areas;
Zone 3. Dry, cropland, natural vegetation, altitude <2,300 m;
Zone 4. Dry, altitude <2,300 m, savannah, grasslands, possibly some croplands.
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Figure 1.5. The four ecological zones of Rwanda. ArcGIS (ESRI, Redland, CA) mapping
of the four ecological zones outlined as polygons (Demanou 2011).
Mosquito species distribution suggests that the most common mosquito species in the
descending order of frequency are Culex sp, Aedes sp, Coquillitedia sp, Mansonia sp,
and Anopheles sp. All of these species are found in high proportions in zone 4 compared
to the other zones (Table 1.2) (Demanou 2011).
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Table 1.2. Number of mosquito species collected by ecological zones during YFV risk
assessment in Rwanda in November-December 2012 (Demanou 2011)

Thus, zone 4 is more suitable for mosquito-borne diseases. By transposition, this zone
corresponds to the Eastern province which is characterized by the highest malaria
prevalence in human population (24% in children under 5 and 12% in individuals older
than age 15) (Rwanda Ministry of Health 2017; USAID 2018). The transmission is
increased during the end of the most intense rainy season and the beginning of the
intense dry season (May-July) as this period is characterized by wet and hot conditions
associated with high mosquito emergence (Rwanda Ministry of Health 2017; Umuhoza et
al. 2017; USAID 2018).
In livestock, for a long time, periods after heavy rain and flooding have been
characterized by tick-borne diseases such as Theileriosis, Babesiosis, and Anaplasmosis
(Rwanda Agriculture Board 2013). Although in neighboring countries like Uganda,
Tanzania, and Kenya several Bunyaviruses such as RVFV, BUNV, Ilesha, Germiston
(Kifaro et al. 2014; Nanyingi et al. 2015; Bird and McElroy 2016; Dutuze et al. 2018) have
been reported and regularly emerge during this period, none of these were reported in
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Rwanda before 2011. The first Bunyavirus to be reported in Rwanda was RVFV in May
2011. This occurred in a cattle farm in Bugesera (zone 4 on Figure 1.5) during unusually
massive abortions in livestock (Rwanda Agriculture Board 2013).
It is speculated that RVFV could have been circulating before under less severe and
unrecognized clinical manifestation. This assumption is also built on the fact that the main
clinical sign of RVF in livestock is abortion which is shared between other common animal
diseases found in Rwanda such as Brucellosis and Theileriosis (Rwanda Agriculture
Board 2013). Since RVFV was first confirmed, sporadic cases are reported countrywide
with more cases from ecological zone 4 and vaccination campaigns are regularly
conducted with emphasis on farms located in this zone. Unfortunately, due to the
insufficiency of laboratory facilities, the diagnosis is mainly clinically or serologically based
after few molecular confirmations. The identification of RVFV in 2011 showed that
Rwanda constitutes a suitable environment for Bunyavirus transmission, thus other
Bunyaviruses such as BUNV and NRIV found in neighboring countries might be
circulating under silent forms.
1.5.

Rationale, hypothesis, and objectives

The genetic relationship between BUNV, BATV, and NRIV viruses raises different
research questions on the potential parallelism in infection kinetics and transmission
dynamics of these viruses. In Rwanda, although RVFV is the only Bunyavirus commonly
reported, given that its diagnosis is mainly based on clinical signs which are common to
a large number of bunyaviral diseases, the suitable environmental conditions, and the
presence of many Bunyaviruses in the neighboring countries, it seems legitimate to

35

speculate that other Bunyaviruses such as BUNV and NRIV (and probably BATV)
circulate in the country.
For the present research project, we hypothesize that given their genetic
relationship, infection kinetics of BUNV, BATV, and NRIV might be related. Further, we
hypothesized that these Orthobunyaviruses circulate in Rwanda and cause infections that
are misclassified as RVFV cases. We decided to test this through the following objectives:
a) Comparatively characterize in vitro infections of BUNV, BATV, and NRIV. This is
addressed in chapter 2 where we offer the comparison of dose-dependent effects
on infection of the three viruses in Vero cells as well as their capabilities to stay
stable after cell death.
b) Comparatively study in vivo infections of BUNV, BATV, and NRIV, and investigate
their potential cross-neutralization. This is covered in Chapter 3 where we
compared the viremia caused by the three viruses in C57Bl/6 mice and quantified
their capabilities to cross-neutralize each other. In addition, we studied the role IRF
3 and IRF 7 in BUNV infection by investigating its pathogenesis IRF 3/7 -/--/- mice.
This is was done in order to create a disease progression model for many
Bunyaviruses presenting similar disease manifestations as BUNV.
c) Investigate the presence of BUNV, BATV, and NRIV in Rwanda. For the first time,
we offer the diagnosis for Bunyaviruses other than RVFV in Rwanda.
1.6.
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CHAPTER 2. COMPARISON OF IN VITRO INFECTION KINETICS
AND EX VIVO STABILITY OF BUNYAMWERA, BATAI, AND NGARI
VIRUSES
2.1. Introduction
Bunyamwera virus (BUNV), Batai virus (BATV), and Ngari virus (NRIV) are mosquitoborne viruses of the Orthobunyavirus genus in the Peribunyaviridae family, one of the ten
virus families comprising the Bunyavirales order (Bowen et al. 2001; Gerrard et al. 2004;
Briese et al. 2006; Groseth et al. 2012; Tauro et al. 2015; King et al. 2018). As with all
members of the Peribunyaviridae family, BUNV, BATV, and NRIV are enveloped viruses
with single-stranded RNA genome made up with three segments, denoted as Small (S),
Medium (M) and Large (L). The S segment encodes the nucleocapsid, the M segment
encodes envelope glycoproteins, and the L segment encodes the polymerase protein (,
Fuller and Bishop 1982; Bowen et al. 2001; Gerrard et al. 2004; Groseth, Weisend, and
Ebihara 2012). NRIV is a natural reassortant of BUNV and BATV and results from a
combination of the BUNV S and L segments and the BATV M segment (Gerrard et al.
2004; Briese et al. 2006; Odhiambo et al. 2014). The relationship of these “parental”
viruses and the “progeny” poses an interesting question, especially given that there is
overlap in their respective transmission and infection ecologies. The existing knowledge
regarding the comparison and contrast of these viruses and what is currently known and
unknown is reviewed in Chapter 1 (Dutuze et al. 2018), and briefly summarized below.
BUNV, the prototype of the Peribunyaviridae family and Bunyavirales order, is the
most characterized of the three, followed by BATV, and lastly NRIV (Briese et al. 2006;
Medlock, Snow, and Leach 2007; Szemiel, Failloux, and Elliott 2012; Riblett and Doms
2016; Dutuze et al. 2018). Investigations of NRIV have mostly focused on the genomic
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(dis)similarities with other members of the Orthobunyavirus genus and the similarity of its
clinical manifestations with Rift Valley Fever virus (RVFV), an important bunyavirus of the
genus Phlebovirus, and family Phenuiviridae (Bowen et al. 2001; Gerrard et al. 2004;
Briese et al. 2006; Jackel et al. 2013, Burleson 2014).
These three Orthobunyaviruses cause disease in domestic ruminants and humans,
with NRIV being epidemiologically associated with hemorrhagic fever in humans in East
Africa (Kenya, Somalia, and Sudan) (Bowen et al. 2001; Gerrard et al. 2004; Briese et al.
2006; Odhiambo et al. 2014). BATV has been isolated across Europe, Asia and Africa,
while BUNV and NRIV remain sporadically isolated in Africa (Smithburn, Haddow, and
Mahaffy 1946; Singh 1966, Gaidamovich et al. 1973, Nashed, Olson, and el-Tigani 1993;
Zeller et al. 1996; Lambert and Lanciotti 2009; Eiden et al. 2014; Liu et al. 2014; Dutuze
et al. 2018). Despite the potential for one or all these viruses to present an emergent
public health threat, they remain relatively under characterized. There have been no
detections of BUNV and BATV concomitantly, though NRIV itself is evidence that this
event must have occurred. BATV was molecularly identified in Uganda in 1967 (East
African Research Institute 1967), highly suspected in Sudan based on serological test in
1988 (Nashed, Olson, and el-Tigani 1993), but otherwise has not been detected in Africa
since. BUNV and NRIV have been identified in many African countries between 1943 and
2015 (shown by Figure 1.2. and extensively reviewed in Chapter 1 (Dutuze et al. 2018).
Importantly, though these viruses are linked genetically and ecologically, there
have been no studies that comparatively characterize the three viruses, especially given
the differences in associated pathogenicity of NRIV compared to BUNV and BATV. Thus,
we compared these three viruses in vitro, reporting growth curves in a commonly used
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cell culture (Vero cells), designed traditional and qRT-PCR assays and report specificity
and sensitivity of such, and describe differences of the in vitro phenotype (plaque
morphologies).
Generally, growth curves of viruses in vertebrate cells consist of four phases, which
are a) adsorption and penetration, b) eclipse, c) maturation, and d) release (Burleson
2014) (Figure 2.1). Adsorption, penetration and eclipse correspond exclusively with the
intracellular phase before the virus starts being detected in both intracellular and
extracellular medium. On the curve, these stages are shown by no to low detection before
the ascendant phase, which corresponds to maturation. Release is translated by
descendant phase on the curve and is followed by no detection of viable virus. This is
due to the fact that cells become metabolically and structurally incapable of supporting
additional replication after the virus production has reached the plateau (Flint 2000).

Figure 2.1. General viral growth curve in mammalian cell
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Preliminary characterization and comparison of these viruses in cell culture is a
necessary first step. Specifically, these phases of the growth curve can provide a means
of laboratory standardization for growth of virus to match titers, and for general use in
experimentation. Additionally, comparative kinetics can give preliminary insights of
important epidemiological concepts such as relative incubation and infectious periods,
especially when comparing across species of viruses where in vivo kinetics are unknown
(Yin and Redovich 2018). Subsequently, these parameters are useful in estimations of
factors important for adequate control measures such as determination of adequate
quarantine periods (Farewell et al. 2005; Nishiura 2007; Chan and Johansson 2012), the
window of efficacious administration of antiviral medication (Lessler et al. 2009), the
identification of potential sources of infection in a population (Lessler et al. 2009), and
establishment of accurate transmission models (Chan and Johansson 2012).
Long-term stability has been studied in members of several families of the
Bunyavirales order such as Phenuiviridae, Nairoviridae and Hantaaviridae (Southam
1954; Hardestam et al. 2007). In general, these viruses can persist for long periods in
less than ideal conditions (such as cell-free conditions). Only one study in 1954
investigated the ex vivo stability of a Peribunyavirus, where BUNV was reported to quickly
disappear from detection (using mouse infectivity titration), though it had been persistently
infecting human lymph nodes in cell culture (Southam 1954). There is no information on
any of the three viruses of interest here on long-term stability in Vero cells – a commonly
used laboratory cell line that is easy to culture and widely used in arbovirology. The
knowledge on the duration of infectiousness of virus in extracellular medium provides a
foundation for establishment of biosafety measures regarding the handling and safe-
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storage of these viruses, as well as inactivation methods. This work provides the first
comparative study of in vitro properties of BUNV, BATV, and NRIV.

2.2. Material and methods
2.2.1. Viruses, plaque assay, and comparative plaque morphology
6547-8, MM2222, and DAK-AR D28542 are the strain designations of BUNV, BATV,
and NRIV respectively used throughout this study. 6547-8 is the prototype strain of BUNV
isolated from Aedes spp. mosquitoes in Uganda in 1943 (GenBank accession numbers:
X14383, M11852, and X73465). MM2222 is the prototype of BATV isolated from Culex
spp. mosquitoes in Malaysia in 1955 (GenBank accession numbers: AB257766,
JX8446595-97, and X73464). DAK-AR D28542 strain of NRIV was isolated from Aedes
spp. male mosquitoes in Senegal in 1985 (GenBank accession number: AY593728-29).
The viruses were obtained from the World Reference Center for Emerging Viruses and
Arboviruses at the University of Texas Medical Branch (UTMB). All viruses were provided
in lyophilized form and were reconstituted by adding 1 mL of cell culture media to the
vials. The passage histories at the time they were received were Suckling mice (SM) 47/
Vero 2, SM3/Vero 2, and SM 4/Baby Hamster Kidney cells (BHK) 1/Vero 2 for BUNV,
BATV, and NRIV, respectively. After reconstitution, the viruses were cultured on Vero
African green monkey kidney cells (ATCC) and stocks were collected at 2 dpi, 5 dpi, and
3 dpi for BUNV, BATV, and NRIV respectively, after observation of cytopathic effects
(CPE). Viral titers were then determined by standard plaque assay techniques. The
calculated titers were 6.65 x 10 6PFU/mL at 3 dpi, 2.27 x 107 PFU/mL at 5 dpi, and 5.7 x
107 PFU/mL at 4 dpi for BUNV, BATV, and NRIV, respectively. Pictures of the plaques of
each virus were taken in a 6-well plate with a ruler on the side. Plaques were
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phenotypically compared and a random sample of 20 plaques per virus were measured
for diameter. BUNV and BATV are biosafety level 2 (BSL-2) viruses while NRIV is a BSL3 virus (CDC, 2019). To control for variation due to environmental conditions, all
experiments were conducted with the LSU School of Veterinary Medicine, Department of
Pathobiological Sciences BSL-3 laboratory.
2.2.2. In vitro growth kinetics and ex vivo stability
a. Comparative growth curves at a Multiplicity of Infection (MOI) of 1
We first studied comparative growth curves of BUNV, BATV, and NRIV grown in Vero
cells under standard conditions at a MOI of 1. For that, Vero African green monkey kidney
cells (ATCC) were grown in optimal medium (88% Medium 199, Earle's Salts, 10% Fetal
Bovine Serum, and 2% Antibiotic-Antimycotic) in T75 flasks at 37˚C, 5% CO2. At 85-90%
confluence, cells were trypsinized and counted using a hemocytometer after being
stained by Trypan Blue (Louis 2011). Cells were then seeded in 6-well plates with a count
of 1.02 x 106 cells in 2 mL of medium per well. After being observed every hour, they were
found to be fully adhered to the flask bottom after 6 hours. Growth media was removed,
and each well was inoculated with an appropriate volume of each virus calculated to have
1.02 x 106 PFU equivalent to a MOI = 1 (Table 2.1). The infections were done in triplicates
per virus. Plates were rocked for 30 mins and incubated at 37 oC, 5% CO2 for 30 minutes
before 2 mL of new media was added to each well. Supernatants were initially collected
from 1 to 7 dpi and stored at -80oC until RNA extraction and amplification. Additional
collection at 10 dpi was done after high concentrations of viral RNA were detected at 7dpi.
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Table 2.1. Volume calculations for BUNV, BATV, and NRIV for 1.02 x 10 6 PFU
considering their titers
Virus

Volume for 1.02 x 106 PFU

BUNV

152µL (titer = 6.65 x 106PFU/mL)

BATV

44.7µL (titer = 2.27 x 107PFU/mL)

NRIV

17.7µL (titer = 5.7 x 107PFU/mL)

b. Dose dependence in vitro growth kinetics under standard growth conditions
Given that mosquitoes inoculate various titers of arboviruses depending on a multitude
of factors, we wanted to characterize and compare the dose-dependence of growth
kinetics of BUNV, BATV, and NRIV in Vero cells (Styer et al. 2007; Secundino et al. 2017;
Talavera et al. 2018). For that, 85-90% confluent 6 well plates of Vero cells grown in
optimal media (88% Medium 199, Earle's Salts,10% Fetal Bovine Serum and 2%
Antibiotic-Antimycotic), and subsequently infected with serially diluted BUNV, BATV, and
NRIV from 106 PFU/mL to 101 PFU/mL. Prior to infection, media was removed from each
well (of 6-well tissue culture plates) and 100 µL of each dilution for each of three viruses
was inoculated onto individual wells. The wells were then rocked for 30 min and incubated
for 30 min at 37oC, 5% CO2. After incubation, 2 mL of new media was added to each well
before incubation again at 37 oC, 5% CO2. Negative control wells with M199E medium
were prepared following the same protocol. 100 µL of supernatant was collected from
each well at 1, 3, 5, 7, 14, and 30 dpi and stored in -80oC until RNA extraction and
amplification.
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c. Stability in extracellular and cell-free media
Given the previous investigation of BUNV extracellular stability by mouse infectivity
titration we wanted to investigate whether BATV or NRIV showed differential stability and
further wanted to determine if stability could be assessed in a more accessible method
since these viruses often affect resource-poor regions (Southam 1954). We investigated
stability by looking at 1) the dose-dependent effect on growth kinetics in Vero cell culture
at less than optimal conditions (2% rather than 10% FBS), 2) the association between
CPE occurrence and viral RNA detection, and 3) long-term stability in cell-free media. For
that, Vero cells were grown in nutrient reduced medium (96%Medium 199, Earle's Salts,
2% Fetal Bovine Serum, and 2% Antibiotic-Antimycotic) at 37˚C in 5% CO2. This is
because with optimal nutrition (10%FBS) cell growth can out-pace cell death, leading to
persistence in cell culture as there are continually more cells to infect. At lower cell
nutrition availability (2%FBS), cell growth is slowed and thus, when compared to the
growth in 10%FBS (see 2.2.2.b), we wanted to determine whether this is persistent
infection or simply viral stability.
After serial dilutions (106 PFU/mL to 101 PFU/mL) of each virus, 85-90% confluent 6
well plates were infected with 100 µL of each dilution for each virus using the protocol
previously described. 100 µL of supernatant was collected from each well at 1, 3, 5, 7,
14, and 30 dpi and stored in -80oC until RNA extraction and amplification. In addition,
cytopathic effect (CPE) was observed under inverted microscope at 20X at various dpi
and pictured with the DINOEYE capture function. Different qualitative scores were given
to each well at 1-14 and 30 dpi according to the relative proportion of dead cells compared
to healthy cells. The scores and description of corresponding CPE are given in Table 2.2.
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Table 2.2. Scores attributed to Cytopathic Effect (CPE)
CPE Score

Corresponding cell culture description

-

No observed CPE

+

Few dead cells

++

Approximately 1/3 cells are dead

+++

Approximately 1/2 cells are dead

++++

Approximately 2/3 cells are dead

+++++

Very few cells still attached as monolayer

++++++

All cells dead (none attached)

To investigate the stability in cell-free media, 100 µL of the each of the three viruses
was inoculated into 2 mL of cell-free M199 1X media in 2 mL Eppendorf tubes. As
previously mentioned, the titers were 6.65 x 10 6PFU/mL, 2.26 x 107 PFU/mL, and 5.7 x
107 PFU/mL for BUNV, BATV, and NRIV, respectively. The tubes were incubated at 37oC,
5% CO2 and 100 µL of supernatant was collected from each tube at 1, 3, 5, 7, 14, and 30
dpi and kept in -80oC until viral RNA extraction and amplification. This experiment was
also run in triplicates.
d. Comparative inactivation by Triton-X-100
Given the potential for long-term stability of these viruses, we tested the ability of
Triton-X-100 – a commonly used detergent used in the development of ELISAs – to
inactivate BUNV, BATV, and NRIV. This was done for potential use of these viruses in
the development of serological assays using less biosafety containment facilities
especially in developing countries where high containment facilities are unavailable. For
that we investigated comparative inactivation of these viruses by Triton-X-100 as this
56

detergent has been used to inactivate other enveloped viruses such as Ebola virus
(Colavita et al. 2017) and influenza (Jonges et al. 2010). 1% Triton-X-100 was added to
the stock of each of the three viruses (5 µL of Triton-X 100 in 495µL viral stock) and the
mixture was incubated at room temperature for 1 hour and kept in -80oC until further use.
To test the efficacy of Triton-X-100 inactivation capacity on these viruses, infectivity of
treated viruses was investigated via CPE appreciation and RNA detection after the
supposedly inactivated viruses were inoculated on Vero cells. Prior to infections, TritonX-100 was removed using the column-based absorption Detergent OUT kit according to
manufacturer instructions (Millipore sigma, Cat No. 2114). 85-90% confluent 6 well plates
of Vero cells were grown in optimal conditions (10%FBS) were used. After removal of the
2 mL growth medium, 100 µL of each virus was inoculated in a well. Plates were then
rocked for 30 mins and incubated at 37oC, 5%CO2 for 30 minutes before addition of 2 mL
of new media. Presence or absence of CPE was observed and 100 µL of the supernatant
was collected every day from 1-7 dpi, and RNA extraction and amplification were
performed as described below. This experiment was also run in triplicates.
e. Determination of viral infectivity after in vitro and ex vivo persistence
Stability (long-term infectivity) of these viruses was investigated by inoculating
supernatants collected at 30 dpi on newly grown Vero cells with optimal medium
concentration. Samples from both the 10% and 2% dose-dependence growth studies that
were collected at 30 dpi were inoculated onto Vero cells. We tested only the viral doses
of 106PFU/mL, 104PFU/mL, and 101PFU/mL of each of the three viruses. 100 µL of 10fold dilution of the supernatants from each %FBS-dose-replicate were inoculated on 8590% confluent 6 well plates of Vero cells. Equivalent experiments were performed for
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supernatants collected at 30 dpi from tubes with cell-free media initially infected with viral
stocks. Collection of these samples was done at 1, 3, 5, and 7 dpi followed by RNA
extraction and amplification. This experiment was also run in triplicates.
2.2.3. Viral RNA detection, qRT-PCR and PCR assay design, and sequencing
RNA was extracted using the KingfisherTM (Thermo-Fisher) automated extraction
platform according to the instructions of manufacturer. A total of 50µL of RNA was
collected for each sample and stored in -80oC until further use.
Both qRT-PCR and traditional PCR primer sets were designed for these viruses for
the M and L segments. This was done because among these Orthobunyaviruses, these
two segments can be used to identify BUNV, BATV, and NRIV. Additionally, for complete
confirmation and exclusion any potential reassortment event in diagnostic process, S
segment primers were designed for traditional PCR. We could not design effective S
segment primers for qRT-PCR.
qRT-PCR primers and probes targeting conserved regions of the M and L segments
of BUNV, BATV, and NRIV were designed using www.idt.dna PrimerQuest tool (Table
2.3). Prior to being used for the experiments, they were tested on viral stocks for
sensitivity and specificity with standard curves generated while titer was determined by
plaque assay as described above. Nucleic acid amplification was performed by qRT-PCR
using the SuperScript™ III One-Step RT-PCR System with Platinum® Taq DNA
Polymerase (Invitrogen, Cat No. 1.1732-088). A PCR mixture of 10µL 2X RT buffer, 1µL
Forward primer (10 µM), 1µL Reverse primer (10 µM), 0.4 µL Probe (20 µM), 0.4 µL SIII
Taq, 1.4 µL ddH2O, 0.8 µL MgSO4 and 5µL RNA was used on 96-well PCR plates. After
being loaded, plates were centrifuged for 2 mins at 2000 rpm prior to actual amplification
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on a Roche Lightcycler® 480 II. The following thermal profile as a cycle of reverse
transcription for 10 min at 50°C, 15 min at 95°C for reverse transcriptase inactivation and
DNA polymerase activation followed by 40 amplification cycles of 15 sec at 95°C
(annealing-extension step) and 30 sec min 40°C (cooling). These cycling conditions were
already used in our laboratory to amplify Zika virus (Faye et al. 2013; Kawiecki et al.
2017). The data were analyzed using Lightcycler® 480 Software.
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Table 2.3. Sequences of primers and probes used for qRT-PCR
Virus and segment
targeted

Primer/probe

BUNV- M

Forward primer
Reverse primer
Probe

BUNV-L

Forward primer
Reverse primer
Probe

BATV-M

Forward primer
Reverse primer
Probe

BATV-L

Forward primer
Reverse primer
Probe

NRIV-M

Forward primer
Reverse primer
Probe

NRIV-L

Forward primer
Reverse primer
Probe

Sequence

GenBank
accession No

5’-GCT TAT GGA TGG GCG TAC AA-3’
5’-GGA GCC ACA GAC ACA ATA TGA-3’
5’-/5Cy5/ATG CAC TTG CGG ATT GGC
AT/3lAbRQSp/-3’
5’-GCC ACT TTG CTG ATT CCT TTG -3’
5’-CTA ACC TTG TAG TGC TGG CTA ATA -3’
5’-/56-FAM/TGG AAG AGG/ ZEN/CAA GCA GAT
TGA GCT/3lABkFQ/-3’
5’-GCA TGT GGA AAC TCA CCA AAT TA-3’
5’-ATT CTT GTG AGG CAG GGA TTA G -3’
5’-/5Cy5/AAG GGA GAA GTG TGG TGT TCA
GGT/3BHQ_2/-3’
5’-CAC TCT ACC AGC TGC ATT CTA C-3’
5’-GTT GAC CAC GGT TCA CTA CTT-3’
5’-/56-FAM/ACAGCTGCA
/ZEN/GGG
ATAATTAACTGG ACC/3lABkFQ/-3’
5’-TAT AGG CCC TTT ACA GCA AGT G-3’
5’-GCT GCA TCC AGG TCT GAT ATT-3’
5’-/5Cy5/ACA TGC GAC GAT AAA GCA AGC
AGA/3lAbRQSp/-3’
5’-GCG AAA CCG TGT AGA AAG TAG A -3’
5’- CCC TGA AAT CAC CGA CCT TTA T -3’
5’-/56-FAM/AGCTTGTGA/ZEN/AAG TGC TTA TTG
TTG TGA TGC/3lABkRQ/-3’
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M11852

X14383

JX846596.1

JX846597.1

KC608153

KC608152

Conventional PCR primers were designed using www.idt.dna PrimerQuest tool as
well (Table 2.4). We endeavored to amplify all three gene segments for future potential
use in sequencing. From RNA extracted as previously described, cDNA was synthesized
using Superscript III First-Strand kit (Invitrogen, Cat No. 18080-051). A mix of 8µL RNA,
1µL of Reverse primer (2µM) and 1 µL dNTPs was done in 200 µL tubes and run on
thermocycler 65oC for 5 min after what 2µL 10X RT Buffer, 4µL 25m MgCl2, 2µL 0.1mm
DTT, 1µL RNase OUT and 1µL Superscript III RT was added before running it back to
the thermocycler for 50oC for 50 min and 85oC for 5 min. 1µL of RNase H was then added
to the tube and put back to the thermocycler again at 37 oC for 20min. A total of amount
21µL cDNA collected and kept at -20oC until further use. cDNA was amplified in 25 µL
PCR mix consisting of 2.5 µL 10X PCR Buffer, 1.5 µL 50mM MgCl2, 0.55 µL 10mM dNTP,
2 µL Forward primer, 2 µL Reverse primer, 0.1 µL Taq, 15.35 µL ddH2O, and 1µL cDNA.
The amplification on thermocycler was performed with the following cycling parameters:
95oC for 15 min; 35 cycles of 94oC for 30 sec, 54oC for 30 sec, 72oC for 1 min and 72oC
for 10 min and 10oC forever. The amplicons were stained by GelRed (Biotum, Cat No.
41003), run on 2% agarose gel with 1X TAE buffer at 100V for 1 hour, and visualized with
Bio View UV Light transilluminator.
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Table 2.4. Primers for conventional PCR
Virus and segment
targeted

Primers

BUNV-S

Forward primer
Reverse primer
Forward primer
Reverse primer
Forward primer
Reverse primer
Forward primer
Reverse primer
Forward primer
Reverse primer
Forward primer
Reverse primer
Forward primer
Reverse primer
Forward primer
Reverse primer
Forward primer
Reverse primer

BUNV- M
BUNV- L
BATV-S
BATV- M
BATV-L
NRIV-S
NRIV-M
NRIV-L

Primer sequence
5’-CTT CCC AGG ATC AGA GAT GTT-3’
5’-ATT TAG CCC GCT GTC TTT CT-3’
5’-GCT TAT GGA TGG GCG TAC AA-3’
5’-GAT GCC TCT GAC CCA GTT AAT-3’
5’-AAT CCA GAG GCC CTA GGT ATA A-3’
5’-GAC CAA GGC TCT TGC TCT ATC- 3’
5’-GAC CCA GAG GTT GCA TAC ATT A-3’
5’-CAG ACC CTG GAA AGA ATG AGA G-3’
5’-GAA CTA ATC CCT GCC TCA CAA G-3’
5’-GAC ACT CTC CTC AAC TGC TTT-3’
5’- TGT ATC ATC ACC CGG CTT ATT C-3’
5’-CAG AGG GTT TGA CAG CCT ATA TT-3’
5’-TGC TAA CAC CAG TAC TTT-3’
5’-ACC TCT GTC GCA TTG TCT TT- 3’
5’-TGG GTG CCT TGC TGT AAA TA - 3’
5’-CAC TGA TCC CTT CAT CCC TAA C- 3’
5’-AGC CAG CAC TAC AAG ATT AGA- 3’
5’-TCT CCT TGC TCA TCA CCA TTA- 3’
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Amplicon
size

GenBank
accession No

395bp D00353.1
651bp NC001926
767bp NC001925
394bp JX846595.1
847bp JX846596.1
798bp JX846597
504bp JX857325.1
914bp KC608153
785bp KC608152

To test the efficiency of our designed traditional PCR primers and confirm the identity
of our viral stocks, we performed sequencing. This was done using Big Dye Terminor
v.3.1 cycle (Applied Biosystems, Cat No.1701127) according to manufacturer’s
instructions and run on the 3130 genetic analyser. Forward and reverse primers for S, M
and L segments for each of the three viruses (BUNV, BATV, and NRIV) were used.
Alignments of obtained sequences were viewed using Bioedit software, USA and subjected
to BLAST search in NCBI GenBank blast tool to identify similar sequences.

2.2.4. Statistics
To determine differences in plaque morphology/size, the diameters of plaques were
compared between viruses by Kruskal-Wallis non-parametric t-test after determining the
data were not normally distributed (Shapiro Wilk, p<0.05).
R package Growthcurver was used to analyze the growth kinetics of BUNV, BATV,
and NRIV across all growth-curve experiments. Growthcurver determines area under the
curve (AUC) and doubling time (DT) used to characterize growth curves. AUC is
determined under the logistic function curve in forms of two metrics: 1) the logistic AUC
(AUC-L) that finds the area under the logistic function that is the best-fit to the data and
2) DT, which is the time that a population takes to double the number of individuals.
Growthcurver determines the fastest DT which occurs when the population is
maximizing its growth potential (Rockwood 2015; Sprouffske and Wagner 2016). For all
growth conditions and for each inoculation dose of each virus, Growthcurver analysis was
performed for all replicates individually and analysis of variance (ANOVA) on AUC-L
(Appendix B) and DT values was performed to compare the growth kinetics among the
three viruses and inoculation doses and different growth cell conditions. When
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significance was determined, Tukey post-hoc test was performed for pairwise
comparisons. Additionally, ANOVA was performed to compare DT of the curves between
cell growth conditions and inoculation doses among viruses.
A paired, one-tailed t-test was performed to test the infectivity of BUNV, BATV, and
NRIV after Triton-X-100 inactivation and after stability at 30 dpi by comparing the RNA
equivalent PFU/mL at day 1 dpi and days 4 or 7 dpi. We determined if the difference of
RNA detected was greater than 0 between 1 and 4 dpi for Triton-X-100 inactivated viruses
and between 1 and 7 dpi for supernatant collected at 30 dpi for the in vitro and ex vivo
stability experiments, then there is evidence of viral replication, indicating the presence
of infectious virus.
2.3.

Results

2.3.1. Plaque assay and plaque morphology
BUNV and NRIV produce a mixture of small, medium, and large sized plaques (Figure
2.2 A-1 & A-3). These plaques are harder to see, and we found that increasing the
concentration of neutral red stain to 0.8mL/25mL of overlay media optimized visualization.
BATV makes well distinguishable plaques that are easily visible at lower neutral red stain
concentration (0.7mL/25mL) (Figure 2.2. A-2). Using Kruskal-Wallis rank sum test, we
determined that BATV produced plaques that had a tendency to be larger than either
BUNV or NRIV. The difference between BATV and BUNV-NRIV was significant by Dunn’s
post hoc test, while plaque diameter was found not to be significant between NRIV and
BUNV (Figure 2.2.B).
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Figure 2.2. Comparative plaque morphology for BUNV, BATV, and NRIV. A-1. BUNV at
4 dpi, A-2. BATV at 5dpi, A-3. NRIV at 4dpi. B. Comparative plaque diameters in mm.
There was a significant difference between BATV and BUNV-NRIV while no significant
difference was found between NRIV and BUNV.
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2.3.2. Specificity and sensitivity of qRT-PCR and PCR
The designed qRT-PCR primers for each virus successfully amplified homologous
self-segments. In addition, there was a successful cross-amplification of BUNV-derived
L-segment primers and the NRIV L gene, and vice versa. The cross-amplification of
BATV-derived M primers and the NRIV M segment was also successful; however, NRIVderived M primers did not amplify the BATV M segment. For our experimental studies,
since no co-infections were performed in vitro, we proceeded with using BUNV M and L
primers and NRIV M and L primers for the detection of all three viruses. Standard curves
generated based on titers calculated from the plaque assays for both M and L primers
had a sensitivity of detection of 101 PFU/mL for all three viruses. Thus, we had a qRTPCR assay that was sensitive and specific given we knew the identity of the infecting
virus of either NRIV or BATV.
Table 2.5. Specificity of qRT-PCR primers
Viruses
Primers
BUNV

BATV

NRIV

BUNV

BATV

NRIV

M

+

-

-

L

+

-

+

M

-

+

+

L

-

+

-

M

-

-

+

L

+

-

+
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We also designed traditional primers for each of the three segments (S, M, and L) of
each of the three viruses and tested for specificity. There was a successful amplification
of virus segments by homologous primers, or primers derived from the matching virus
(Figure 2.3.A). Across the shared segments between BUNV and NRIV (S and L), the
cross-amplification was successful as well, while the cross-amplification of the shared
segment between BATV and NRIV (M) was not very successful. NRIV M primers weakly
amplified the BATV M segment (Figure 2.3.C) while BATV M primers did not amplify the
NRIV M at all (Figure 2.3.B).
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Figure 2.3. Specificity of designed primers for conventional PCR. A. Amplification by
homologous primers. B. Comparison between amplification of NRIV genome segments
by homologous primers and its parental genome segment primers, C. Comparison
between amplification of BUNV (S, L) and BATV (M) genome segments by homologous
primers and by NRIV primers.
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An alignment of the GenBank sequences associated with these viruses after we
sequenced using designed primers for traditional PCR (Table 2.4.) showed the similarity
percentages displayed in Table 2.6. The low similarity percentages between BATV M and
NRIV M segments (87.23% and 89.55%) might be associated with failure of BATV M and
NRIV M primers to amplify each other.
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Table 2.6. GenBank similarity percentages of BUNV, BATV, and NRIV segment alignments using the designed traditional
PCR primers (BUNV: strain 6547-8, BATV:M2222 strain, and NRIV: DAK-AR-D2852)
Similarity percentages
BUNV-S

BUNV-M BUNV-L

BATV-S

BATV-M

BATV-L

NRIV-S

NRIV-M

NRIV-L

Primer targets
BUNV-S

95.95%

BUNV-M

91.67%
99.66%

BUNV-L

99.59%

BATV-S

97.25%
99.7%

BATV-M

98.02%

BATV-L
NRIV-S

99.86%
100%

100%

NRIV-M
NRIV-L

87.23%

89.55%
97.39%

99.29%
99.79%
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2.3.3. In vitro growth kinetics of BUNV, BATV, and NRIV
2.3.3.1.

Growth curves under standard conditions

a. Comparative growth curves at MOI of 1
Analysis of variance of AUC-L shows that there was no difference of growth between
viruses and target for RNA amplification (M and L segments). Since there was no
difference between M and L primers for specificity or for apparent detection in growth
curves, we proceeded with the use of M primers for the rest of our study. Figure 2.4.
shows the average growth curves for each virus and log (PFU/mL) determined by qRTPCR for the M segment (Figure 2.4 A) and the L segment (Figure 2.4 B.). No difference
was determined via ANOVA (p>0.05).

Figure 2.4. Growth curves of BUNV, BATV, and NRIV in standard cell culture condition
(10%FBS), at a MOI of 1 for quantification by A. M primers B. L primers.
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b. Inoculation dose dependence for growth kinetics
A MOI of 1 was equivalent to 106 PFU and may have led to early saturation of cells by
viruses, thus masking a critical difference in early eclipse and maturation stages that
might be dose-dependent. Thus, we decided to investigate differences due to inoculation
dose. Using ANOVA, we found no significant defect of virus identity on the growth curves.
However, a significant effect of inoculation dose was found, though this was not surprising
(p<0.05). Using the Tukey post-hoc comparison, we determined the significant
differences to be between 106 and 101PFU/mL (p < 0.0001), 106 and 104PFU/mL
(p=0.041), and 104 and 101PFU/mL (p=0.025). Growth curves for high initial doses
peaked earlier than those for low initial doses on average by 1-2 days (Figure 2.5).
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Figure 2.5. BUNV, BATV, and NRIV growth kinetics in Vero cells grown in standard conditions (10%FBS) with different
inoculation doses. (106-1 PFU/mL). Error bars represent standard errors.
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For doubling times, ANOVA using DT values for all replicates, each taken individually did
not show any significant difference between viruses. However, there was a significant
difference between initial doses. Using the Tukey post-hoc comparison, we determined the
significant differences to be between 10 6 and 101PFU/mL (p < 0.0001), 106 and 104PFU/mL
(p=0.0408), and 104 and 101PFU/mL (p=0.025). The means of DT values and peak days per
inoculation dose for each virus are shown in Table 2.7.
Table 2.7. Peak days and Doubling Times (DT) for growth curves of BUNV, BATV, and NRIV
with standard cell culture conditions (10%FBS)
Virus

Inoculation titer (log PFU/mL) Peak day

Doubling time

BUNV

6
5
4
3
2
1
6
5
4
3
2
1
6
5
4
3
2
1

0.32
0.24
0.25
0.36
0.28
0.48
0.32
0.44
0.25
0.36
0.28
0.63
0.21
0.27
0.33
0.18
0.29
0.29

BATV

NRIV

4
5
5
5
7
7
3
4
5
5
7
7
3
3
6
6
6
7

74

In the course of this investigation, we determined that viral RNA was still detected at 30
dpi when cells were presumably dead. We then hypothesized that there was viral stability of
these viruses in the absence of viable cells in which to replicate. This led to a series of
experiments to characterize the stability of these viruses. The course and logical framework
of the remaining results are depicted in Figure 2.6.
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Figure 2.6. Logic framework of in vitro and ex vivo growth kinetics study of BUNV, BATV, and NRIV.
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2.3.3.2.

Investigation of viral stability

a. Viral kinetics in Vero cells grown in less nutritious medium
Analysis of variance of AUC-L values showed that there were significant effects of
both viral identity and inoculation dose. Pair-wise comparison by Tukey post-hoc test on
viral identity showed that only BUNV and BATV were different (p=0.009). For post-hoc
comparisons of inoculation doses, differences were found between 10 6 and 101PFU/mL
(p<0.0001), 106 and 104PFU/mL (p=0.0253), and 104 and 101PFU/mL (p< 0.0001).
Average growth curves for each virus at 2% FBS and 10 6-101 PFU/mL inoculation doses
are shown in (Figure 2.7.).
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Figure 2.7. BUNV, BATV, and NRIV growth kinetics in Vero cells grown in sub-standard conditions (2%FBS) with different
inoculation doses (106-1PFU/mL). Error bars indicate represent standard errors.
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Generally, BUNV and NRIV infected cell culture showed faster CPE than BATV infected
cell culture. At 10 dpi all cells were visibly not viable after infection with all viruses at all
inoculation doses. BATV infected cell culture did not show any signs of CPE at 1 dpi at any
inoculation dose, while BUNV and NRIV showed early CPE at higher inoculation doses
(Table 2.8). As shown by CPE visualization, viral RNA was still detected long after all cells
of the monolayer were dead.
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Table 2.8. Gradual CPE during persistent infections of BUNV, BATV, and NRIV in Vero cells at 10%FBS
Virus

Titer at
0 dpi (PFU/mL)
BUNV 106
105
104
103
102
101
BATV 106
105
104
103
102
101
NRIV 106
105
104
103
102
101

1dpi

2dpi

3dpi

4dpi

5dpi

6dpi

7dpi

8dpi

9dpi

10dpi

+
+
+
+
+
-

++
++
+
+
++
+
+
+
+
++
++
++
++
+
-

++++
++++
++++
+++
++
+
+++
++
++
+
+
+
++++
+++
++
++
+
+

+++++
+++++
+++++
++++
+++
++
++++
++++
+++
++
+
+
+++++
++++
++++
++
++
++

+++++
+++++
+++++
++++
+++
++
++++
++++
+++
++
+
+
+++++
+++++
++++
++
++
++

+++++
+++++
+++++
++++
++++
+++
+++++
+++++
++++
+++
+++
++
++++++
+++++
++++
++++
+++
++

++++++
++++++
+++++
++++
++++
++++
+++++
+++++
+++++
++++
++++
+++
++++++
+++++
++++
++++
+++
+++

++++++
++++++
++++++
++++++
+++++
+++++
++++++
++++++
+++++
++++
++++
++++
++++++
++++++
++++++
+++++
++++
++++

++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
+++++
+++++

++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++
++++++

-: No CPE observed
+: few dead cell
++: approximately 1/3 of cells are dead
+++: approximately ½ of cells are dead
++++: approximately 2/3 of cells are dead
+++++: very few cells still attached
++++++: all cells are dead (no cell attached

80

For doubling times, ANOVA using DT values for all replicates, each taken individually
significant differences between viruses and inoculation doses. By Tukey post-hoc test, a
difference was found to be between BUNV and BATV (p=0.009), however no difference
was found between BUNV and NRIV (p>0.05), and between BATV and NRIV (p>0.05).
Regarding inoculation doses, differences were found between 106 and 101PFU/mL (p <
0.0001), 106 and 104PFU/mL (p=0.025), and 104 and 101PFU/mL (p< 0.0001). The means
of the DT values and peak days per inoculation dose for each virus are shown in Table
2.9.
Table 2.9. Peak days and Doubling Times for growth curves of BUNV, BATV, and NRIV
in sub-standard cell culture (2%FBS)
Virus
BUNV

BATV

NRIV

Inoculation
PFU/mL)
6
5
4
3
2
1
6
5
4
3
2
1
6
5
4
3
2
1

titer

(log Peak day
4
4
4
4
7
7
3
7
7
7
7
7
3
3
4
4
7
7

Doubling Time
0.08
0.09
0.13
0.13
0.23
0.33
0.1
0.51
0.43
0.6
0.76
0.78
0.14
0.09
0.21
0.21
0.18
0.59

When we compared growth kinetics between optimal conditions (10% FBS) from
section 2.2.2 and 2% FBS cell culture conditions within viruses, the analysis of doubling
time within viruses showed that there was a significant difference for BUNV.
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The DT was doubled when BUNV was inoculated on cells grown in standard
conditions compared to sub-standard conditions. No difference was found for BATV and
NRIV between both cell culture conditions (Table 2.10).
Table 2.10. Comparison of DT for standard and sub-standard cell culture conditions
within viruses
DT

BUNV

BATV

NRIV

Mean

se

p-value

10%FBS

0.32

0.082

0.0156

2%FBS

0.16

0.088

10%FBS

0.38

0.128

2%FBS

0.53

0.229

10%FBS

0.26

0.051

2%FBS

0.23

0.16

0.2376

0.7553

b. Stability of BUNV, BATV, and NRIV
-

Infectivity after stability for 30 dpi

BUNV, BATV, and NRIV inoculated in vitro with both optimal (10% FBS) and suboptimal (2% FBS) conditions were shown to be stable in the absence of replication up to
30 dpi. The titers of supernatant collected from high (106PFU/mL), medium (104PFU/mL),
and low (101PFU/mL) inoculation doses at 30 dpi are given in Table 2.11.
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Table 2.11. Viral titers of supernatants collected at 30 days post-inoculation
Virus

% FBS

BUNV

10
10
10
2
2
2
10
10
10
2
2
2
10
10
10
2
2
2

BATV

NRIV

Inoculation dose (log
PFU/mL)
1
4
6
1
4
6
1
4
6
1
4
6
1
4
6
1
4
6

Viral titer of supernatant collected
at 30 dpi (log PFU/mL)
6
6
6
6
7
7
6
6
6
7
7
7
7
7
7
7
8
8

Supernatant from the 30 dpi collections were inoculated on Vero cells and collected
at several time-points post-inoculation. We used a paired t-test to determine if there was
a significant increase in viral titer from 1 dpi to 7 dpi, indicating replication and thus
infectious virus. For each virus and %FBS condition, at least 2 out of 3 inoculations
showed definite signs of replication (Figure 2.8. and Table 2.12.). This indicates that these
three Orthobunyaviruses are stable in extracellular conditions.
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Figure 2.8. Comparative infectivity of BUNV after in vitro persistence at 30 dpi from cells both grown in standard (10%FBS)
and sub-standard conditions (2%FBS).
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Figure 2.9. Comparative infectivity of BATV after in vitro persistence at 30 dpi from cells both grown in standard (10%FBS)
and sub-standard conditions (2%FBS).
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Figure 2.10. Comparative infectivity of NRIV after in vitro persistence at 30 dpi from cells both grown in standard (10%FBS)
and sub-standard conditions (2%FBS).
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- Ex vivo viral stability
For the viruses kept in cell-free M199 medium at 37 oC, viral RNA was still detected at
30dpi. A decline of the curves was observed, correctly indicating no viral replication
without cells; however, the final detected titers at 30 dpi were still relatively high 10 4-105
PFU/mL for BUNV and BATV, and higher than 105.75PFU/mL for NRIV.

Figure 2.11. Ex vivo stability of BUNV, BATV, and NRIV. The inoculation doses were viral
stock titers (106PFU/mL for BUNV, 107PFU/mL for both BATV and NRIV)
Similarly, tests to determine infectiousness of virus collected from the media-only
experiment at 30 dpi showed that only BUNV was still infectious at 30 dpi. A paired t-test
comparing the replication titers at 1 and 7 dpi of supernatant collected at 30 dpi from cell87

free medium infected by BUNV, BATV, NRIV showed only a significant difference for
BUNV (p=0.03333).
No differences were found for supernatants of BATV and NRIV (Table 2.12). This
indicates that BATV and NRIV are probably not replicating after staying in ex vivo
conditions for 30 days.

Figure 2.12. Infectivity of BUNV, BATV, NRIV after stability in ex vivo conditions.
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Table 2.12. Analysis of infectivity of supernatant collected at 30 dpi
Virus

BUNV

Cell growth
condition/ ex
vivo
10%

2%

BATV

Ex vivo
10%

2%

NRIV

Ex vivo
10%

2%

Ex vivo

Initial inoculation
dose (log
PFU/mL)
6
4
1
6
4
1
6
6
4
1
6
4
1
7
6
4
1
6
4
1
7

Analysis of infectivity of 30 dpi
supernatant, p-value (paired t test
analysis between 1 and 7 dpi)
0.1972 (NS)
0.002565
0.03954
0.04028
0.0005203
0.1407 (NS)
0.03333
0.01851
0.03436
0.04964
0.0482
0.008229
0.05556 (NS)
0.1387 (NS)
0.03759
0.01472
0.002535
0.007274
0.01645
0.005696
0.416 (NS)

NS: No significant difference
c. Comparative inactivation by Triton-X-100
No CPE was observed on Vero cell monolayers infected with 1%Triton-X inactivated
BUNV, BATV, and NRIV before 5 dpi. However, for all three viruses, viral RNA was
detected up to 7 dpi (Figure 2.13). A paired t test showed that there was no difference
between RNA concentration at 1 and 4 dpi indicating that the viruses were not infectious.
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Figure 2.13. Viral RNA detection of BUNV, BATV, and NRIV after 1% Triton-X-100
inactivation.
2.4.

Discussion
These viruses have the potential to become emergent public health threats to animals

and people and gaining a basic understanding of their behaviors in common laboratory
systems is a necessary first step in getting “ahead of the curve”. Further, experimental
studies in mammalian cell lines give insight into how the viruses may comparatively
behave in mammalian host cells. Thus, this study provides a first glimpse into the infection
kinetics of BUNV, BATV, and NRIV at different infective doses, and this study is the first
to directly compare in vitro growth kinetics of BUNV, BATV, and NRIV.
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First, we describe diagnostic assays to be used for field detection and other laboratory
studies of these viruses. We showed that our designed BATV primers did not amplify the
NRIV M segment as well as expected, while the BUNV and NRIV cross-amplification
consistently performed well. However, the BATV and NRIV M segments have a range of
similarity of 89.3-96.0% (Briese et al. 2006) while the BUNV and NRIV S and L segments
have a range of similarity of 99.6-99.8% and 98.5-99.8% respectively (Groseth, Weisend,
and Ebihara 2012). This potential for lower genetic similarity of BATV and NRIV could be
the cause of decreased efficacy of the BATV M primers for NRIV and/or vice versa.
We demonstrated that BUNV and NRIV produce more heterogeneous sized plaques
while BATV plaques were more homogeneous, despite NRIV and BATV sharing the gene
segments that regulate Bunyavirus entry into the cell (M segment). The M segment
encodes the glycoproteins Gn and GC, which are responsible for viral attachment to host
cells and may be involved in entry into the cell, though the mechanism of cell entry for
Bunyaviruses remains largely unknown (Albornoz et al. 2016). However, plaque size
between NRIV and BATV was not different, while BUNV plaque sized tended to be
smaller than the other two viruses. Previous studies identified small and large plaques of
BUNV and NRIV as different isolates and were associated with different pathogenesis
profiles in mice (Odhiambo et al. 2014). Large plaque isolates grew to higher titers but
were less virulent than small plaque isolates (Odhiambo et al. 2014). Given our results
and this study, it is possible that the BUNV and NRIV stocks are a mixture of different
isoforms or that these viruses have an inherent propensity to produce different isoforms
in mammalian cell systems. In other viruses such as Zika virus, different plaque
phenotypes have been associated with passage history or host species ((Moser et al.
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2018). The lack of variability in BATV virus plaque morphology might point to a more
consistent viremia profile in mammalian systems, especially given its lack of association
with severe disease in mammals. It has been proposed that viremia profiles of
arboviruses in some hosts are “slow-and-steady” compared to the fast-peak but fastcessation profile in humans or other vertebrate hosts. This “tortoise-hare” model was
proposed as an alternative strategy by the virus to infect as many mosquitoes as possible
through longer viremic periods, even with lower systemic titers (Althouse and Hanley
2015). It may be that BATV utilizes the “tortoise” model while BUNV and NRIV are more
“hare”. Ecologically, this could make sense as BATV has been proposed to infect mostly
birds, where long and persistent infections have been seen with other arboviruses like
West Nile (Komar et al. 2003; Nemeth et al. 2009; Wheeler et al. 2012; Reisen et al.
2013).
We also found that there were no significant differences among these viruses in their
growth kinetics, regardless of cell culture conditions (% FBS) or inoculation doses. Of
course, the correlation between the growth curves and clinical manifestation in vivo
should also be investigated for direct comparisons and estimations of infectivity in
humans and other natural hosts. However, we did determine that to fully assess
infectivity, it is better to dilute the virus to a titer below a MOI of 1 (at a titer of 10 4 PFU/mL
per 106 cells, e.g.) as the higher inoculation doses apparently saturated the system.
Viruses are obligate intracellular organisms. Thus, for viral replication, viable
host cells are necessary. However, we demonstrated that these viruses were stable
outside of viable cell culture and maintained infectiousness for at least 30 dpi under
laboratory conditions. The phenomenon of viral stability has been found in other
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Bunyaviruses: Rift Valley Fever Virus (Phenuiviridae family) (Billecocq, Vialat, and Bouloy
1996), Toscana virus (Phenuiviridae family) (Verani, Nicoletti, and Marchi 1984) and
Dugde virus (Nairoviridae family) (David-West and Porterfield 1974). In all these cases,
viral inocula were enriched in deferring interfering (DI) particles which seem to be
associated with persistent infections (David-West and Porterfield 1974; Verani, Nicoletti,
and Marchi 1984; Billecocq, Vialat, and Bouloy 1996). Defective interference with large
deletions in the L RNA segment has been reported in BUNV infected baby hamster kidney
(BHK) cells (Scallan and Elliott 1992). Further investigations need to be conducted in
Vero cells especially in relation to persistent infections. Toscana infected Vero cells were
morphologically similar to parental cells and didn’t show any CPE (Verani, Nicoletti, and
Marchi 1984) contrary to BUNV, BATV, and NRIV infected Vero cells in our study.
Previous studies have reported long-term viral stability in other Bunyaviruses: Sandfly
Fever Sicilian Virus (SFSV), a sandfly-borne virus of the Phenuiviridae family; Hantaan
virus, a rodent-borne virus of the Hantaviridae family; and Crimean-Congo Hemorrhagic
Fever Virus (CCHV) of Nairoviridae family (Hardestam et al. 2007). The epidemiological
relevance of stability harkens back to RVFV, which has also been found to be stable for
long time in the environment (Craig, Thomas, and DeSanctis 1967, Miller 1962). In the
case of RVFV, environmental contamination from abortions or slaughter (and thus
association with ex vivo stability) is a major source of human-acquired cases (Yuill 1991;
Archer et al. 2011; OIE 2016; Clark et al. 2018).
Given that these Orthobunyaviruses are also associated with abortions and
hemorrhagic manifestations similar to RVFV, it could be postulated that dead hosts and

93

infective tissues might be sources of infectious virus from the environment for relatively
long periods, provided permissive conditions (humidity, temperature, etc.).
For the purposes of diagnostic development, we showed that 1%Triton-X-100 can be
used to inactivate BUNV, BATV, and NRIV. This could have useful applications such as
ELISA design for detecting exposure to these viruses since there are no such
commercially available kits. The use of inactivated viruses is especially important in
developing parts of the world which lack biosafety facilities required to handle infectious
viruses. At the laboratory level, the combination of viral stability and Triton-X-100
inactiviation should be taken into account in the design and implementation of the
laboratory biosafety measures.
Summary
We provide a comparative analysis of the in vitro kinetics of BUNV, BATV, and NRIV
and conclude that growth kinetics are not different among them. However, we also
provide preliminary characterization of and diagnostic assays for these viruses for
laboratories or field studies looking to work with these viruses, so they do not have to
“start from scratch.” We also provide an important biosafety and epidemiological finding
of the stability of these viruses and determine the utility of a common detergent in
inactivating these viruses for the purpose of further diagnostic development.
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CHAPTER 3. PRELIMINARY IN VIVO INVESTIGATION OF
BUNYAMWERA, BATAI, AND NGARI VIRUSES
3.1. Introduction
Bunyamwera (BUNV), Batai (BATV), and Ngari (NRIV) viruses are members of
Orthobunyavirus genus in the Peribunyaviridae family of the Bunyavirales order involved
in a reassortment process as NRIV is a natural reassortant of the other two (Bowen et al.
2001; Weisend, and Ebihara 2012; King et al. 2018, Groseth; Maes et al. 2019). As
mentioned in previous chapters, members of this family are characterized by singlestranded RNA genome partitioned into three segments Small (S), Medium (M), and Large
(L). In the Peribunyaviridae family, S segment encodes nucleoprotein (N) and nonstructural protein (NSs), M segment encodes glycoproteins (Gn and Gc) and nonstructural protein (NSm) while L segment encodes polymerase protein (Elliott 1996;
Schmaljohn 2001; Bioinformatics Swiss Institute 2010; Elliott 2013; Elliott 2014). The
NRIV genome consists of the S and L genome segments from BUNV and the M segment
from BATV (Gerrard et al. 2004; Briese et al. 2006). The M segment gene products (Gc
and Gn) are known to be major determinants of host range, tissue tropism,
transmissibility, neutralization, and hemagglutination (Beaty et al. 1981; Shope, Rozhon,
and Bishop 1981; Castrucci 1993). In addition, NSm, another M segment gene product,
partially contributes to the virulence (Elliott 1996; Bridgen et al. 2001; Kohl et al. 2003;
Elliott 2013; Soldan and González-Scarano 2014; Otieno 2015).
Subsequently, reassortants have been speculated to share similar aspects with their
genetic parents from which they got M segment (Otieno 2015). However, apart from
reassortants which share the entirety of M segment with the donor viruses, it has been
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shown that Gn and Gc have conserved regions shared among a large number of viruses
within genus. These conserved regions are at the basis of antigenic relationships within
the genus, leading to antibody cross-neutralization. For many years, as genome
sequences were scarce, Bunyaviruses were classified into serogroups based on these
antigenic relationships detected by hemagglutination inhibition and neutralization tests
(Elliott 1996; Cheng et al. 200; Elliott 2013; Otieno 2015).
BUNV and BATV were found to cross-react between themselves and with more than
30 other viruses belonging to the same Bunyamwera serogroup, one of seventeen (17)
in Orthobunyavirus genus (Table 1.1) (Eley et al. 1989; Mohamed, McLees, and Elliott
2009; Elliot 2013; Dutuze et al. 2018). However, after NRIV was confirmed as reassortant
between BUNV and BATV, no study has been conducted to test the abilities of NRIV to
cross-neutralize BUNV and BATV and vice-versa.
BUNV, BATV, and NRIV have all been shown to cause diseases in both humans and
animals. However, although they are connected this genetic phenomenon, the diseases
associated with these viruses in vertebrate hosts are dissimilar in pathogenesis and
virulence. BATV is characterized by low virulence, BUNV by moderate virulence, and
NRIV has been shown to be the most virulent of the three (Southam and Moore 1951;
Kokernot et al. 1958; Nashed, Olson, and el-Tigani 1993; Edwards 1994; Gerrard et al.
2004; Briese et al. 2006; Eiden et al. 2014; Tauro et al. 2015). Unfortunately, these
differences in virulence and pathogenesis are compared mainly by observational studies
from clinical cases isolated during outbreaks or other field occurrences.

Very few

experimental studies have been conducted to characterize these aspects adequately.
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Like for other viral infections, immune responses against these Bunyaviruses inckude
type I interferons as a come in front line in innate immunity (Garcia-Sastre and Biron 2006;
Stetson and Medzhitov 2006). Type I interferons (IFN-α/β) are produced and secreted by
cells in response to viral infection and activate the expression of so-called IFN-stimulated
genes (ISGs) in neighboring cells.
Many ISGs encode proteins with the ability to directly or indirectly inhibit virus
multiplication. The expression of IFN genes is enhanced by different transcription factors
such as IRF3, IRF7, NF-kB and AP-1 (Garcia-Sastre and Biron 2006; Kawai and Akira
2006; Stetson and Medzhitov 2006; Elliott and Weber 2009). The importance of IFNs in
bunyaviral infections has been confirmed by studies showing that several Bunyaviruses
can be inhibited by IFNs (Luby 1975; Tamura et al. 1987; Morrill et al. 1989; Temonen et
al. 1995; Livonesi et al. 2007; Habjan et al. 2009). In addition to mouse models indicating
that mice lacking functional type I IFN receptors are highly susceptible to infection with
BUNV, La Crosse virus (LACV), Dugbe virus (DUGV), Hantaan virus (HTNV), and Rift
Valley Fever virus (RVFV) (Hefti et al. 1999; Bouloy et al. 2001; Weber et al. 2001;
Wichmann et al. 2002; Boyd, Fazakerley, and Bridgen 2006; Blakqori et al. 2007).
Although BUNV is the prototype of Bunyavirales order, and therefore should be
extensively studied for better understanding the infections by viruses of this order, there
are still few available mouse models for infection by this virus. These include the
comparison of pathogenesis of wild-type BUNV and BUNdelNSs (NSs deleted mutant) in
5-week-old BALB/c (Bridgen et al. 2001), description of brain lesions in two-day-old ICR
Swiss mice (Murphy, Harrison, and Tzianabos 1968), and comparison of pathogenicity of
small and large BUNV plaques in (1–4 day-old) and 6-week-old Swiss Albino suckling
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mice (Odhiambo et al. 2014). All of these models focus on the description of occurrences
of clinical manifestations and mortality. Histological lesions for this infection are less
investigated as only brain lesions are described only after intracerebral inoculation
(Murphy, Harrison, and Tzianabos 1968; Bridgen et al. 2001).
In this study, we investigated the comparative infection kinetics of BUNV, BATV, and
NRIV in C57BL/6 (wild type) mice and quantified the potential of BUNV, BATV, and NRIV
to cross-neutralize each other. In addition, we investigated the role of IRF3 and IRF7 in
BUNV infection by characterizing phenotypically and histopathologically the pathogenesis
in IRF3/7 double knock out (-/--/-) mice.
3.2 . Material and methods
3.2.1. Viruses
As previously mentioned in chapter 2, viral stocks used in this research project were
BUNV strain 6547-8 with a titer of 6.65x106PFU/mL, BATV strain MM2222 with the titer
of 2.27 x 107PFU/mL, and NRIV strain DAK AR D 2854 with the titer of 5.7x107PFU/mL.
For infection of C57BL/6 mice aimed at comparatively characterizing BUNV, BATV, and
NRIV infection kinetics, the three viruses were used after matching titers at 10 6 plaque
forming units (PFU)/mL. For the characterization of pathogenesis of BUNV in IRF 3/7

-/--/-

mice, only BUNV was used at 103PFU/mL.
3.2.1 Mice and infections
a. Viremia and neutralization study of BUNV, BATV, and NRIV in wild type mice
Fifteen 10-week-old C57BL/6 mice were put into three groups of five each. Each group
was inoculated one of the three viruses (BUNV, BATV, and NRIV). Mice were inoculated
by subcutaneous injection with 100µL of 6.65x106PFU/mL, 2.27x106PFU/mL, and
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5.7x106PFU/mL respectively for BUNV, BATV, and NRIV. Inoculated mice bled at 1, 3,
5, 7, and 30 days post-infection (dpi). Blood samples collected at 1, 3, 5, and 7 dpi was
used to study comparative viremia of these viruses while blood samples collected at 30
dpi served at serum collection for homologous and cross-neutralization study. Samples
were incubated for 30 mins at room temperature and centrifugated for 4 minutes at 6,000
rcf and 4°C. Serum was then separated from clot and kept in -80oC until ready to use. For
the viremia study, viral RNA was extracted and amplified while plaque reduction
neutralization tests (PRNTs) were performed for serological investigation.
b. BUNV pathogenesis in IRF 3/7-/--/- mice
Eight (8) female IRF3/7 double knock out mice were used for these experiments. The
mice were 8 to 9 weeks old at the date of inoculation. Prior to the actual infection
experiment, a male mouse was subcutaneously inoculated with 100 µL of 6.65 x
105PFU/mL for an infection test. The mouse died at 4 dpi. From that infection test, we
decided to infect the 8 females with a lower titer hoping that they would survive longer for
more appreciation of clinical manifestations and lesions. Mice were then subcutaneously
inoculated with 100 µL of 6.65 x 103 PFU/mL of BUNV. They were weighed every day
until 6 dpi and bled every day until 4 dpi. They could not be bled after 4 dpi because of
severe vascular lesions. As for C57BL/6 mice infection, blood samples were incubated
for 30 minutes at room temperature and serum was collected after centrifugation (6,000
rcf, 4 mins, 40C). Serum was then separated from the clot and stored at -80oC until viral
RNA extraction and amplification.
After death, all mice were opened on the abdominal line for complete multisystemic
gross examination. Three mice were placed in 10% neutral buffered formalin and sent to
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a histopathology laboratory for analysis. Tissues were then dehydrated in alcohol and
xylene and embedded in paraffin. 5 μm thick tissue sections were then obtained for slide
preparation before being stained with hematoxylin and eosin and coverslipped. After
slides were examined via light microscopy, pathological changes were recorded by
certified pathologists of the American College of Veterinary Pathologists (ACVP) board at
the LSU School of Veterinary Medicine.
3.2.2. Viral RNA extraction and qRT-PCR
RNA extraction was performed using the KingfisherTM (Thermo-Fisher) automated
extraction platform (according to the instructions of manufacturer) as previously
described. Viral RNA was detected by qRT-PCR using the SuperScript™ III One-Step
RT-PCR System with Platinum® Taq DNA Polymerase (Life Technologies) on a Roche
Lightcycler® 480 (Roche). We used primers and probes targeting the M segments (Table
2.3).
3.2.3. Plaque Reduction Neutralization Test (PRNT)
Vero African green monkey kidney cells (ATCC) were grown under optimal growth
conditions (88% Medium 199, Earle's Salts, 10% Fetal Bovine Serum, and 2% AntibioticAntimycotic) at 37˚C, 5% CO2 were used to perform PRNT. Serum samples collected at
30 dpi for each mouse were serially diluted in plain M199E as follows: 1:20, 1:40,
1:80, 1:160, 1:320, 1:640, 1:1280, 1:2560, 1:5120, and 1:10240. Before performing
cross-neutralization assays, homologous neutralization assays were performed to check
the antibody production level for each group. For cross-neutralization study assay,
neutralization of each virus by the antibodies produced against the other two was studied
in a pairwise way as presented in Table 3.1. PRNTs were performed following WHO
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protocol for Dengue virus (OIE 2017), previously used in our lab for both Dengue and
Zika viruses (Kawiecki and Christofferson 2016; Kawiecki et al. 2017), and briefly
described below. Diluted sera were heat inactivated at 56 oC for 30 min before, 100µL of
viral mix (viral stock diluted in M199E medium) containing 50 PFU was added to 100µL of
each serum dilution. The mixes virus/diluted sera samples were then incubated at 37oC
for 1 hour. After removal of the maintenance media on confluent 6 well plates, the virusserum mix was added, with each well corresponding to a specific serum dilution. Plates
were then rocked for 30 mins at room temperature and incubated for 30 mins at 37oC. An
additional positive control well with only 100 µL of 50 PFU of virus was prepared to serve
in the calculation of plaque number reduction as well as a negative control well with only
100 µL of M199E media. Positive and negative controls all received the same treatment
as other wells with serum dilutions. 3 mL of overlay media was added to each well and 2
mL of second overlay media was added at 3 dpi for both BUNV and NRIV, and at 4 dpi
for BATV.
Table 3.1. Homologous and cross-neutralization study plan
Assay

Virus to neutralize

Serum used

Homologous neutralization

BUNV
BATV
NRIV
BUNV

BUNV
BATV
NRIV
BATV
NRIV
BUNV
NRIV
BUNV
BATV

Cross-neutralization

BATV
NRIV
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3.2.4. Statistics
Weight loss was reported as the percent reduction compared to initial weight. For
BUNV, BATV, and NRIV infected C57BL/6 mice and BUNV infected IRF3/7 mice, viremia
titers reported are log10 transformed titers by qRT-PCR.
For homologous and cross-neutralization experiments, PRNT50 and PRNT80 titers
were expressed as the reciprocal of the highest dilution at which the 50% and 80% of
plaque reduction was achieved.
3.3.

Results

3.3.1. In vivo infections kinetics of BUNV, BATV, and NRIV in C57BL/6 mice
a. Viremia curves
Neither BUNV nor BATV were detected after 3 dpi, and only one NRIV infected mouse
presented with what looked like viremia peaking at 3 dpi. Although there was no increase
in viral titers, for the other four NRIV infected mice, viral RNA was detected up to 5 dpi
(Figure 3.1).
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Figure 3.1. Comparative viremia curves of BUNV, BATV, in NRIV in C57bl/6 mice.
b. Homologous and cross-neutralization experiments
As expected, it was found that BUNV, BATV, and NRIV all cross-neutralize each other.
However, the levels of neutralization differ depending on antibodies and the virus being
neutralized. The averages of neutralization titers for all pairs of neutralization are
summarized in Table 3.2. NRIV was the most efficient at both self and crossneutralization, BUNV self and cross-neutralized at a moderate level while BATV was the
least efficient at both.
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Table 3.2. PRNT50 and PRNT80 titers for homologous and cross-neutralization BUNV,
BATV, and NRIV.

BUNV
Antibodies PRNT50
PRNT80
BUNV
4736
272
BATV
656
<20
NRIV
944
40

Virus neutralized
BATV
PRNT50
PRNT80
384
128
<20
<20
2816
1280

NRIV
PRNT50 PRNT80
320
20
<20
<20
>10240
3456

The detailed neutralization profiles for all dilutions of BUNV antibodies for homologous
(neutralization of BUNV) and cross-neutralization (neutralization of BATV and NRIV) are
represented by Figure 3.2.
Figure 3.2 also provides detailed neutralization profiles for all dilutions of BATV
antibodies

for

homologous

(neutralization

of

BATV)

and

cross-neutralization

(neutralization of BUNV and NRIV). It was found that these antibodies did not neutralize
any of these viruses to 80% reduction. No reduction of 50% was obtained for crossneutralization (neutralization of BUNV and NRIV) while for homologous neutralization was
achieved at high serum dilutions (PRNT50 of 656 as shown in Table 3.2). This could be
an indication that BATV infected C57BL/6 mice did not produce a large amount of
antibodies.
NRIV was the most efficient at both self-neutralization and neutralization of its genetic
parents as shown by titers in Table 3.2 and in more details provided in Figure 3.4. At
dilution of 1:10240 (the last for our experiment), the homologous neutralization was still
higher than 50% reduction, showing a strong self-neutralization. NRIV antibodies
neutralize BATV more than BUNV. The observed PRNT50 were 2816 and 944 for BATV
and BUNV respectively. And the observed PRNT80 titers were 1280 and 40 for BATV
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and BUNV respectively. This is not surprising as BATV and NRIV have similar
glycoproteins, which serve as triggers of neutralizing antibody production.
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Figure 3.2. Comparative homologous and cross-neutralization profiles for BUNV, BATV, and NRIV for different serum
dilutions.
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3.3.2. Pathogenesis of BUNV infection in IRF 3/7

-/--/-

mice

a. Clinical manifestations
By 3 dpi, all mice (100%) had shown signs of illness such as lethargy and hunched
posture. Facial swelling was observed in 3 mice (37.5%) (as shown by Figure 3.3).
Mortality was observed starting at 4 dpi and was at 100% at 6dpi.

Figure 3.3. Dead BUNV infected IRF 3/7

-/--/-

mouse with facial swelling.

b. Weight loss, viremia, and survival
The highest weight loss was observed from 1 to 3 dpi (Fig 3.4 A). All mice were
viremic but peak days were not well identified due to the rapid mortality (Figure 3.4.B).
The survival percentage was 100% up to 3dpi, 37.5% at 4dpi, 12.5% at 5dpi and 0% at
6dpi (Figure 3.4.C).

113

Figure 3.4. Weight loss, viremia and survival curves of BUNV infected IRF 3/7
C. Survival curves.
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-/--/-

mice. A. Weight loss, B. Viremia,

c. Histopathological lesions
The disease was multisystemic causing mainly necrotic lesions in the liver, lungs,
spleen, bone marrow, reproductive system (uterus and ovaries), and skin with vascular
necrosis.
The liver was affected by severe random acute coagulative necrosis (framed area on
Figure 3.5.A) with multifocal single cell necrosis, (red arrows on Figure 3.7.B) and portal
hepatitis (black arrow on Figure 3.5.B).

Figure 3.5. Necrotic lesions of the liver of BUNV infected IRF3/7 -/--/- mice. A. Liver severe
ample necrosis (10X), B. Liver single cell necrosis and portal hepatitis (40X).
In the lungs, there was intravascular leukocytosis (black arrow on Figure 3.6.A), cell
death (black arrows on Figure 3.6.B), and mild incipient accumulation of inflammatory
cells in lung parenchyma (framed on Figure 3.6.B). Additionally, there was a mediastinal
steatitis (framed on Figure 3.6.C), and vascular necrosis characterized by loss of structure
of endothelial cells (black arrow on Figure 3.6.C).
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Figure 3.6. Necrotic and inflammatory lesions of the lung of BUNV infected IRF3/7 -/--/mice A. Lung intravascular leukocytosis (40X), B. Lung intravascular leukocytosis and
leukocyte death (40X), C. Lung mediastinal steatitis and vascular necrosis (40X).
The lymphoid organs associated with immune response were necrotic (Figure 3.7.A).
The bone marrow was affected by multifocal necrosis and the spleen by a severe
perifollicular necrosis (framed on Figure 3.7.B).

Figure 3.7. Necrotic lesions of lymphoid organs in BUNV infected IRF3/7 -/--/- mice. A.
Bone marrow necrosis (40X), B. Spleen perifollicular pulp severe necrosis (40X).
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In the reproductive system, there was a multifocal necrotizing oophoritis in the ovary
follicle (framed on Figure 3.8.A) and a mild multifocal necrosis in endometrium (black
arrows on Figure 3.8.B).

Figure 3.8. Necrotic lesions of reproductive system of BUNV infected IRF3/7 -/--/- female
mice, A. Ovary necrotizing oophoritis (20X), B. Mild endometrium necrosis(40X).

The disease was also characterized by necrosis of the skin (Figure 3.9. A). In the
eyelids, there was severe diffuse acute edema expanding the loose connective tissue,
and dilatation of lymphatics (Figure 3.9.B). These changes were responsible for the
prominent facial swelling.

Figure 3.9. Lesions associated with facial swelling. A. Skin necrosis and mast cell
degranulation (40X), B. Eyelid severe diffuse edema (20X).
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No significant lesions were observed in the brain, kidneys, adrenal glands, esophagus,
stomach and intestine, skeletal muscle, bone, pancreas, thyroid, or parathyroid.
3.4.

Discussion

In this study, we compare in vivo infections of BUNV, BATV, and NRIV, provide a
cross-neutralization study including NRIV, and provide multisystemic histological
characterization of BUNV associated lesions in IRF3/7 -/--/- mice.
This study shows that immunocompetent 6-week old C57BL/6 mice are not
susceptible to either BUNV, BATV, or NRIV infection. Although no clinical sign was
noticed, NRIV was the only virus to be detected up to 3 dpi, while BUNV and BATV were
only detected at 1 dpi. This extended detection of NRIV could be one indication of its
increased virulence compared to BUNV and BATV.
Previous experimental studies have shown that suckling (2 day-old) ICR Swiss mice
inoculated intracerebrally by BUNV (infectivity dose of 1010 LD50/mL) started dying after
53 hours after developing severe encephalitis. Viremic titers increased progressively and
plateaued at 16h (Murphy, Harrison, and Tzianabos 1968). Another study showed that
when BUNV and NRIV (infectivity doses of 109PFU/mL) were used to intraperitoneally
infect both 6-week-old and suckling (1-4 days old) Swiss Albino mice, 6-week-old mice
were not susceptible to any of the two infections, while suckling mice died between 2 and
6 days after showing neurological symptoms such as limb paralysis, tremors, and
disorientation (Odhiambo et al. 2014). All these studies including ours, indicate that
suckling wild type inoculated both intracerebrally and intraperitoneally as well as adult
wild type mice inoculated intracerebrally are severely susceptible to BUNV and NRIV
infections and die quickly starting at 2 dpi.
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However, adult wild type mice inoculated intraperitoneally and subcutaneously are not
susceptible to infection BUNV, BATV, and NRIV.
Neutralization assays showed that BUNV, BATV, and NRIV all self and crossneutralize each other though levels of neutralization differ. BUNV and BATV crossneutralization is not surprising as they belong to the same Bunyamwera serogroup.
Viruses within this serogroup have previously shown cross-neutralization (Hunt and
Calisher 1979). However, this is the first study including their reassortant in crossneutralization investigation. NRIV was the most efficient at both self and crossneutralization, BUNV self and cross-neutralized at a moderate level, and BATV was the
least efficient at both. The low homologous neutralization might indicate low antibody
production by C57BL/6 mice.
It was noticed that NRIV strongly neutralized BATV, which is not surprising because
the two viruses have similar glycoproteins, which serve as triggers for neutralizing
antibodies (Elliott 1996; Yandoko et al. 2007; Elliott 2013; Elliott 2014; Soldan and
González-Scarano 2014). However, BATV did not cross-neutralize BUNV and NRIV nor
itself very efficiently. As previously mentioned, this could be related to a low level of BATV
antibody production by C57BL/6. The epidemiological relevance of this crossneutralization is that an infection to any of these three viruses will lead to protection of the
next infection of any of these three viruses. This is important especially for BUNV and
NRIV which have overlapping distributions in Africa (Zeller et al. 1996; Bowen et al. 2001;
Wertheim 2012; Dutuze et al. 2018). The high neutralization of BATV by both BUNV and
NRIV combined with its low virulence leading to non-specific alarming symptoms, could
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be the reasons why BATV isn’t well investigated in Africa, where BUNV and NRIV are
known to circulate.
In previous a study on homologous and heterologous neutralization of viruses of the
Bunyamwera serogroup, it was found that the PRNT90 of homologous neutralizations
were 1800 and 5100 for BUNV (RI-1 strain) and BATV (MM2222 strain), respectively. The
ratios of homologous: heterologous titers to the nearest whole number were all 91 for
BATV neutralization by BUNV and vice-versa (Hunt and Calisher 1979).
The difference between these findings and ours may come from the difference in mice
strains used, though in the study discussed, mice strain used was not specified.
In this study, we also showed that IRF3/7

-/--/-

mice are susceptible and severely

affected by BUNV infection, contrary to wild type mice, which did not show any sign of
sickness, this highlights the importance of type I IFN in fighting BUNV infection. The
histological characteristics show that the disease was multisystemic affecting different
organs such as the lungs, liver, and organs of the reproductive system (uterus, ovaries).
The main lesion found in necropsy was hemprrhage in abdominal cavity while the main
histopathological lesions were necrosis and inflammation. Although BUNV infection has
not been associated with hemorrhagic fever in either humans nor animals, hemorrhage
in abdominal cavity found in IR3/7 -/--/- shows that this virus has the potential to do so,
especially in immunocomprised individuals.
Similar lesions have been observed in an experimental study of another member of
Orthobunyavirus genus, Schmallenberg virus (SBV). When 0.86x10 3 50% tissue culture
infectious doses of SBV was used to subcutaneously inoculate 8-week-old type I IFN
receptor knock out (IFNAR-/-), mice presented with diffusely discolored livers, large
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amounts of blood in abdominal cavities, and internal bleeding into the small intestine. In
histopathology, the liver presented severe hepatocellular degeneration and necrosis
(Wernike et al. 2012).
These studies confirm the role of type I IFN in immune response to Orthobunyaviruses
and indicate that these are highly necrotic viruses that have a high potential to produce
hemorrhagic fevers especially in immunocomprimised individuals.

As BUNV is the

prototype of the Peribunyaviridae family and of Bunyavirales order in general, this study
could be a model of Bunyaviral infection in IRF 3/7 -/--/- mice.
3.5.

References

Beaty, B. J., M. Holterman, W. Tabachnick, R. E. Shope, E. J. Rozhon, and D. H. Bishop.
1981. "Molecular basis of bunyavirus transmission by mosquitoes: role of the
middle-sized RNA segment." Science 211 (4489):1433-5.
Bioinformatics Swiss Institute. 2010. "Orthobunyavirus." Viral Zone.
Blakqori, G., S. Delhaye, M. Habjan, C. D. Blair, I. Sánchez-Vargas, K. E. Olson, G.
Attarzadeh-Yazdi, R. Fragkoudis, A. Kohl, U. Kalinke, S. Weiss, T. Michiels, P.
Staeheli, and F. Weber. 2007. "La Crosse bunyavirus nonstructural protein NSs
serves to suppress the type I interferon system of mammalian hosts." J Virol 81
(10):4991-9. doi: 10.1128/JVI.01933-06.
Bouloy, M., C. Janzen, P. Vialat, H. Khun, J. Pavlovic, M. Huerre, and O. Haller. 2001.
"Genetic evidence for an interferon-antagonistic function of rift valley fever virus
nonstructural protein NSs." J Virol 75 (3):1371-7. doi: 10.1128/JVI.75.3.13711377.2001.
Bowen, M. D., S. G. Trappier, A. J. Sanchez, R. F. Meyer, C. S. Goldsmith, S. R. Zaki, L.
M. Dunster, C. J. Peters, T. G. Ksiazek, S. T. Nichol, and R. V. F. Task Force.
2001. "A reassortant bunyavirus isolated from acute hemorrhagic fever cases in
Kenya and Somalia." Virology 291 (2):185-90. doi: 10.1006/viro.2001.1201.
Boyd, A., J. K. Fazakerley, and A. Bridgen. 2006. "Pathogenesis of Dugbe virus infection
in wild-type and interferon-deficient mice." J Gen Virol 87 (Pt 7):2005-9. doi:
10.1099/vir.0.81767-0.
Bridgen, A., F. Weber, J. K. Fazakerley, and R. M. Elliott. 2001. "Bunyamwera bunyavirus
nonstructural protein NSs is a nonessential gene product that contributes to viral
121

pathogenesis."
Proc
10.1073/pnas.98.2.664.

Natl

Acad

Sci

U

S

A

98

(2):664-9.

doi:

Briese, T., B. Bird, V. Kapoor, S. T. Nichol, and W. I. Lipkin. 2006. "Batai and Ngari
viruses: M segment reassortment and association with severe febrile disease
outbreaks in East Africa." J Virol 80 (11):5627-30. doi: 10.1128/JVI.02448-05.
Castrucci, M. R., Donatelli, I., Sidoli, L., Barigazzi, G., Kawaoka, Y., & Webster, R. G. .
1993. "Genetic reassortment between avian and human influenza A viruses in
Italian pigs." Virology 193 (1):503-506.
Cheng, L. L., K. T. Schultz, T. M. Yuill, and B. A. Israel. 2000. "Identification and
localization of conserved antigenic epitopes on the G2 proteins of California
serogroup
Bunyaviruses."
Viral
Immunol
13
(2):201-13.
doi:
10.1089/vim.2000.13.201.
Dutuze, M. F., M. Nzayirambaho, C. N. Mores, and R. C. Christofferson. 2018. "A Review
of Bunyamwera, Batai, and Ngari Viruses: Understudied Orthobunyaviruses With
Potential One Health Implications."
Front Vet Sci 5:69. doi:
10.3389/fvets.2018.00069.
Edwards, J. F. 1994. "Cache Valley virus." Vet Clin North Am Food Anim Pract 10
(3):515-24.
Eiden, M., A. Vina-Rodriguez, B. O. El Mamy, K. Isselmou, U. Ziegler, D. Hoper, S. Jackel,
A. Balkema-Buschmann, H. Unger, B. Doumbia, and M. H. Groschup. 2014. "Ngari
virus in goats during Rift Valley fever outbreak, Mauritania, 2010." Emerg Infect
Dis 20 (12):2174-6. doi: 10.3201/eid2012.140787.
Eley, S. M., J. I. Delic, R. M. Henstridge, L. G. Bruce, C. R. Humphreys, and N. F. Moore.
1989. "Bunyaviridae. Serological relationships." Microbiologica 12 (4):351-67.
Elliot, R. M. and C.S. Schmaljohn. 2013. In Fields Virology. Springer Science & Business
Media
Elliott, R. M. 2014. "Orthobunyaviruses: recent genetic and structural insights." Nat Rev
Microbiol 12 (10):673-85. doi: 10.1038/nrmicro3332.
Elliott, R. M. . 1996. The Bunyaviridae. New York, N.Y: Plenum Press
Elliott, R. M., and F. Weber. 2009. "Bunyaviruses and the type I interferon system."
Viruses 1 (3):1003-21. doi: 10.3390/v1031003.
Elliott, Richard M. 2013. The bunyaviridae: Springer Science & Business Media.

122

Garcia-Sastre, A., and C. A. Biron. 2006. "Type 1 interferons and the virus-host
relationship: a lesson in detente."
Science 312 (5775):879-82. doi:
10.1126/science.1125676.
Gerrard, S. R., L. Li, A. D. Barrett, and S. T. Nichol. 2004. "Ngari virus is a Bunyamwera
virus reassortant that can be associated with large outbreaks of hemorrhagic fever
in Africa." J Virol 78 (16):8922-6. doi: 10.1128/JVI.78.16.8922-8926.2004.
Groseth, A., C. Weisend, and H. Ebihara. 2012. "Complete genome sequencing of
mosquito and human isolates of Ngari virus." J Virol 86 (24):13846-7. doi:
10.1128/JVI.02644-12.
Habjan, M., A. Pichlmair, R. M. Elliott, A. K. Overby, T. Glatter, M. Gstaiger, G. SupertiFurga, H. Unger, and F. Weber. 2009. "NSs protein of rift valley fever virus induces
the specific degradation of the double-stranded RNA-dependent protein kinase."
J Virol 83 (9):4365-75. doi: 10.1128/JVI.02148-08.
Hefti, H. P., M. Frese, H. Landis, C. Di Paolo, A. Aguzzi, O. Haller, and J. Pavlovic. 1999.
"Human MxA protein protects mice lacking a functional alpha/beta interferon
system against La crosse virus and other lethal viral infections." J Virol 73
(8):6984-91.
Hunt, A. R., and C. H. Calisher. 1979. "Relationships of bunyamwera group viruses by
neutralization." Am J Trop Med Hyg 28 (4):740-9.
Kawai, T., and S. Akira. 2006. "Innate immune recognition of viral infection." Nat Immunol
7 (2):131-7. doi: 10.1038/ni1303.
Kawiecki, A. B., and R. C. Christofferson. 2016. "Zika Virus-Induced Antibody Response
Enhances Dengue Virus Serotype 2 Replication In Vitro." J Infect Dis 214
(9):1357-1360. doi: 10.1093/infdis/jiw377.
Kawiecki, A. B., E. H. Mayton, M. F. Dutuze, B. A. Goupil, I. M. Langohr, F. Del Piero,
and R. C. Christofferson. 2017. "Tissue tropisms, infection kinetics, histologic
lesions, and antibody response of the MR766 strain of Zika virus in a murine
model." Virol J 14 (1):82. doi: 10.1186/s12985-017-0749-x.
King, A. M. Q., E. J. Lefkowitz, A. R. Mushegian, M. J. Adams, B. E. Dutilh, A. E.
Gorbalenya, B. Harrach, R. L. Harrison, S. Junglen, N. J. Knowles, A. M. Kropinski,
M. Krupovic, J. H. Kuhn, M. L. Nibert, L. Rubino, S. Sabanadzovic, H. Sanfacon,
S. G. Siddell, P. Simmonds, A. Varsani, F. M. Zerbini, and A. J. Davison. 2018.
"Changes to taxonomy and the International Code of Virus Classification and
Nomenclature ratified by the International Committee on Taxonomy of Viruses
(2018)." Arch Virol 163 (9):2601-2631. doi: 10.1007/s00705-018-3847-1.

123

Kohl, A., R. F. Clayton, F. Weber, A. Bridgen, R. E. Randall, and R. M. Elliott. 2003.
"Bunyamwera virus nonstructural protein NSs counteracts interferon regulatory
factor 3-mediated induction of early cell death." J Virol 77 (14):7999-8008. doi:
10.1128/jvi.77.14.7999-8008.2003.
Kokernot, R. H., K. C. Smithburn, B. De Meillon, and H. E. Paterson. 1958. "Isolation of
Bunyamwera virus from a naturally infected human being and further isolations
from Aedes (Banksinella) circumLuteolus theo." Am J Trop Med Hyg 7 (6):57984.
Livonesi, M. C., R. L. de Sousa, S. J. Badra, and L. T. Figueiredo. 2007. "In vitro and in
vivo studies of the Interferon-alpha action on distinct Orthobunyavirus." Antiviral
Res 75 (2):121-8. doi: 10.1016/j.antiviral.2007.01.158.
Luby, J. P. 1975. "Sensitivities of neurotropic arboviruses to human interferon." J Infect
Dis 132 (4):361-7. doi: 10.1093/infdis/132.4.361.
Maes, P., S. Adkins, S. V. Alkhovsky, T. Avšič-Županc, M. J. Ballinger, D. A. Bente, M.
Beer, É Bergeron, C. D. Blair, T. Briese, M. J. Buchmeier, F. J. Burt, C. H. Calisher,
R. N. Charrel, I. R. Choi, J. C. S. Clegg, J. C. de la Torre, X. de Lamballerie, J. L.
DeRisi, M. Digiaro, M. Drebot, H. Ebihara, T. Elbeaino, K. Ergünay, C. F. Fulhorst,
A. R. Garrison, G. F. Gāo, J. J. Gonzalez, M. H. Groschup, S. Günther, A. L.
Haenni, R. A. Hall, R. Hewson, H. R. Hughes, R. K. Jain, M. G. Jonson, S. Junglen,
B. Klempa, J. Klingström, R. Kormelink, A. J. Lambert, S. A. Langevin, I. S.
Lukashevich, M. Marklewitz, G. P. Martelli, N. Mielke-Ehret, A. Mirazimi, H. P.
Mühlbach, R. Naidu, M. R. T. Nunes, G. Palacios, A. Papa, J. T. Pawęska, C. J.
Peters, A. Plyusnin, S. R. Radoshitzky, R. O. Resende, V. Romanowski, A. A. Sall,
M. S. Salvato, T. Sasaya, C. Schmaljohn, X. Shí, Y. Shirako, P. Simmonds, M.
Sironi, J. W. Song, J. R. Spengler, M. D. Stenglein, R. B. Tesh, M. Turina, T. Wèi,
A. E. Whitfield, S. D. Yeh, F. M. Zerbini, Y. Z. Zhang, X. Zhou, and J. H. Kuhn.
2019. "Taxonomy of the order Bunyavirales: second update 2018." Arch Virol 164
(3):927-941. doi: 10.1007/s00705-018-04127-3.
Mohamed, M., A. McLees, and R. M. Elliott. 2009. "Viruses in the Anopheles A,
Anopheles B, and Tete serogroups in the Orthobunyavirus genus (family
Bunyaviridae) do not encode an NSs protein." J Virol 83 (15):7612-8. doi:
10.1128/JVI.02080-08.
Morrill, J. C., G. B. Jennings, T. M. Cosgriff, P. H. Gibbs, and C. J. Peters. 1989.
"Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha." Rev
Infect Dis 11 Suppl 4:S815-25.
Murphy, F. A., A. K. Harrison, and T. Tzianabos. 1968. "Electron microscopic
observations of mouse brain infected with Bunyamwera group arboviruses." J Virol
2 (11):1315-25.

124

Nashed, N. W., J. G. Olson, and A. el-Tigani. 1993. "Isolation of Batai virus
(Bunyaviridae:Bunyavirus) from the blood of suspected malaria patients in Sudan."
Am J Trop Med Hyg 48 (5):676-81.
Odhiambo, C., M. Venter, K. Limbaso, R. Swanepoel, and R. Sang. 2014. "Genome
sequence analysis of in vitro and in vivo phenotypes of Bunyamwera and Ngari
virus isolates from northern Kenya."
PLoS One 9 (8):e105446. doi:
10.1371/journal.pone.0105446.
Organization, World Health. 2007. Guidelines for plaque reduction neutralization testing
of human antibodies to dengue viruses. Geneva.
Otieno, Odhiambo Collins. 2015. "Circulation, reassortment and transmission of ngari and
bunyamwera viruses in northern Kenya." PhD diss., University of Pretoria.
Schmaljohn, C. S. . 2001. "Bunyaviridae: the viruses and their replication." Fields of
Virology.
Shope, R. E., E. J. Rozhon, and D. H. Bishop. 1981. "Role of the middle-sized bunyavirus
RNA segment in mouse virulence." Virology 114 (1):273-6.
Soldan, S. S., and F. González-Scarano. 2014. "The Bunyaviridae." Handb Clin Neurol
123:449-63. doi: 10.1016/B978-0-444-53488-0.00021-3.
Southam, C. M., and A. E. Moore. 1951. "West Nile, Ilheus, and Bunyamwera virus
infections in man." Am J Trop Med Hyg 31 (6):724-41.
Stetson, D. B., and R. Medzhitov. 2006. "Type I interferons in host defense." Immunity
25 (3):373-81. doi: 10.1016/j.immuni.2006.08.007.
Tamura, M., H. Asada, K. Kondo, M. Takahashi, and K. Yamanishi. 1987. "Effects of
human and murine interferons against hemorrhagic fever with renal syndrome
(HFRS) virus (Hantaan virus)." Antiviral Res 8 (4):171-8.
Tauro, L. B., M. E. Rivarola, E. Lucca, B. Marino, R. Mazzini, J. F. Cardoso, M. E.
Barrandeguy, M. R. Teixeira Nunes, and M. S. Contigiani. 2015. "First isolation of
Bunyamwera virus (Bunyaviridae family) from horses with neurological disease
and an abortion in Argentina." Vet J 206 (1):111-4. doi: 10.1016/j.tvjl.2015.06.013.
Temonen, M., H. Lankinen, O. Vapalahti, T. Ronni, I. Julkunen, and A. Vaheri. 1995.
"Effect of interferon-alpha and cell differentiation on Puumala virus infection in
human monocyte/macrophages." Virology 206 (1):8-15.
Weber, F., E. F. Dunn, A. Bridgen, and R. M. Elliott. 2001. "The Bunyamwera virus
nonstructural protein NSs inhibits viral RNA synthesis in a minireplicon system."
Virology 281 (1):67-74. doi: 10.1006/viro.2000.0774.
125

Wernike, K., A. Breithaupt, M. Keller, B. Hoffmann, M. Beer, and M. Eschbaumer. 2012.
"Schmallenberg virus infection of adult type I interferon receptor knock-out mice."
PLoS One 7 (7):e40380. doi: 10.1371/journal.pone.0040380.
Wertheim, H. F., Horby, P., & Woodall, J. P. (Eds.). 2012. Atlas of human infectious
diseases.
Wichmann, D., H. J. Gröne, M. Frese, J. Pavlovic, B. Anheier, O. Haller, H. D. Klenk, and
H. Feldmann. 2002. "Hantaan virus infection causes an acute neurological disease
that is fatal in adult laboratory mice."
J Virol 76 (17):8890-9. doi:
10.1128/jvi.76.17.8890-8899.2002.
Yandoko, E. N., S. Gribaldo, C. Finance, A. Le Faou, and B. H. Rihn. 2007. "Molecular
characterization of African orthobunyaviruses." J Gen Virol 88 (Pt 6):1761-6. doi:
10.1099/vir.0.82643-0.
Zeller, H. G., M. Diallo, G. Angel, M. Traore-Lamizana, J. Thonnon, J. P. Digoutte, and
D. Fontenille. 1996. "[Ngari virus (Bunyaviridae: Bunyavirus). First isolation from
humans in Senegal, new mosquito vectors, its epidemiology]." Bull Soc Pathol
Exot 89 (1):12-6.

126

CHAPTER 4. IDENTIFICATION OF ORTHOBUNYAVIRUS INFECTIONS
IN CATTLE DURING A RIFT VALLEY FEVER OUTBREAK IN RWANDA
IN 2018
4.1. Introduction
Members of the Bunyavirales order have caused diseases of zoonotic and
economic importance globally since the beginning of the 20th century (Briese, Calisher,
and Higgs 2013; Elliott 2013; Clark et al. 2018; Dutuze et al. 2018).
In Africa, the most ancient and most devastating Bunyavirus is Rift Valley Fever Virus
(RVFV) (Genus: Phlebovirus, Family: Phenuiviridae,) was first identified and
characterized in 1912 and further detected as etiological agent of fatal epizootic outbreak
in Kenya in 1930 (Stordy 1913; Daubney, Hudson, and Garnham 1931; Baba et al. 2016).
RVFV is a vector-borne virus that causes disease in humans, livestock, and wildlife
ruminant species (Daubney, Hudson, and Garnham 1931; Ikegami 2011; Bird and
McElroy 2016; Clark et al. 2018). In animals, it is clinically characterized by abortions and
stillbirths, hepatitis, and hemorrhagic fever in severe cases (Daubney 1931; Findlay 1931;
Easterday 1965; Ikegami 2011). In humans, the mild form is characterized by self-limiting
febrile illnesses, but individuals may progress to severe disease manifesting as
hemorrhagic fever, encephalitis, vision loss and conjunctivitis (Freed 1951; van Velden et
al. 1977; Laughlin et al. 1978; Salib and Sobhy 1978; Strausbaugh et al. 1978; Siam,
Meegan, and Gharbawi 1980; Deutman and Klomp 1981; Ikegami 2011). These clinical
manifestations are common in many diseases caused by Bunyaviruses (Elliott 1996;
Elliott 2013; Soldan and González-Scarano 2014). Although RVFV has a broad range of
identified vectors consisting of mosquitoes, ticks, and flies, the primary vectors are Aedes
spp and Culex spp mosquitoes (Daubney R. 1932; Lee 1979; Davies and Highton 1980;
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Linthicum, Davies, et al. 1985; Linthicum, Kaburia, et al. 1985; Pepin et al. 2010;
Fontenille et al. 1998; Labuda and Nuttall 2004). RVFV consistently circulates in domestic
ruminants and human populations throughout different countries of Africa and the Arabian
Peninsula where it causes significant outbreaks associated with livestock mortality,
associated economic losses, and human mortalities (Woods 2002; Balkhy and Memish
2003; Archer et al. 2011; Baba et al. 2016; Samy, Peterson, and Hall 2017; Budasha et
al. 2018; Clark et al. 2018; Georges et al. 2018). The virus is maintained during
interepidemic periods by transovarial transmission in Aedes mosquitoes and the
resurgence of outbreaks is facilitated by periodic rainfall and flooding due to the
intertropical convergence of air currents from southern and northern hemispheres which
leads to a seasonal emergence of infected Aedes spp. (Linthicum et al. 1999). After the
emergence of infected Aedes mosquitoes, an outbreak may be sparked but the epidemic
is likely maintained by Culex spp. (Linthicum et al. 1999). In East Africa, this cycling
pattern has been recognized since the 1970s with large outbreaks occurring in 1977
(Egypt) (Siam, Meegan, and Gharbawi 1980), in 1997-1998 (Kenya) (Woods 2002), in
2006-2008 (Somalia, Tanzania, and Kenya) (WHO 2007; Anyangu et al. 2010), and 2018
(Kenya, Uganda and Rwanda) (OIE 2018; WHO 2018).
In Rwanda, the only Bunyavirus regularly surveilled is RVFV. The first molecularly
confirmed case of RVFV was reported in Bugesera in 2011 after unusually high rate of
abortions in domestic ruminants (mainly cattle) during the period of May to June (Rwanda
Agriculture Board 2013; Umuhoza et al. 2017). Since that time, RVFV has become
endemic with sporadic cases reported year-round in the Eastern part of the country, and
higher intensity outbreaks in May-June and December-January following the rainy
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seasons of March-April and October-November (Rwanda Agriculture Board 2013;
Umuhoza et al. 2017). For prevention, livestock are recommended to be regularly
vaccinated with live attenuated Rift Valley Fever vaccine prepared from Smithburn’s
attenuated strain of RVF virus (RIFTVAX) (Rwanda Agriculture Board 2013). However,
vaccine uptake and compliance rates are unknown.
Although RVF is the most recognized and significant arbovirus in the region, many
other zoonotic Bunyaviruses such as Bunyamwera virus (BUNV), Batai virus (BATV), and
Ngari virus (NRIV), circulate in East Africa. BUNV was first identified in Uganda (1943)
and since has been regularly found in Tanzania, Kenya, and Uganda between 1945 and
2012 (Kokernot et al. 1958; Wertheim 2012; Otieno 2015; Dutuze et al. 2018). BATV was
first identified in Uganda (1966) and highly suspected in Sudan by serological assay
(1988) (Singh 1966; Nashed, Olson, and el-Tigani 1993). NRIV was first identified as an
etiological agent of fatal hemorrhagic fever outbreak in Kenya (1997-1998) (Gerrard et al.
2004; Briese et al. 2006; Otieno 2015). Despite their obvious potential to be of public and
one health importance, BUNV, BATV, and NRIV are not ordinarily included in diagnostic
panels, and could be cryptically circulating throughout Sub-Saharan Africa.
BUNV, BATV, and NRIV belong to the taxonomic genus Orthobunyavirus, and NRIV
is the natural reassortant of BUNV and BATV (SBUNV MBATV LBUNV) (Zeller et al. 1993).
BUNV, BATV, and NRIV are transmitted by similar vectors as RVFV, infect similar
vertebrate hosts, and infection with these viruses have been characterized with similar
clinical manifestations (Gerrard et al. 2004; Briese et al. 2006).
In 2018, there was unusually heavy rainfalls that led to explosion of RVFV in East
African countries (Rwanda, Kenya, Uganda, and Tanzania). This was the most intense
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occurrence of RVF in Rwanda as it caused many cases of death and/or abortion cases
in the ruminant population (OIE 2018). In addition, there was likely an underreporting of
RVFV cases of small ruminants due to their low economic and cultural importance in
Rwanda. Diagnosis of cattle was primarily by clinical manifestations, not by molecular
techniques.
Thus, we tested samples from acutely ill ruminants from Rwanda during the May-June
2018 outbreak using conventional PCR to molecularly confirm RVFV and to test the
hypothesis that BUNV, BATV, or NRIV might be co-circulating (Dutuze et al 2018).
4.2. Material and methods
4.2.1. Sample collection and handling
One hundred and fifty-seven (157) blood samples were collected from cattle and
twenty-eight (28) from goats suspected of RVFV infection in different parts of the country
between May 29 and July 25, 2018. The inclusion criteria for blood collection were (at
least one of them): having aborted in less than a week, presenting signs of hemorrhagic
fever, history of death suspected for RVF in same farm in less than 3 days, and history of
abortion suspected to be associated with RVF in less than 3 days. Calves whose mothers
presented signs of hemorrhagic fever or have died suspected of RVF with 3 days were
sampled as well.
Figure 4.1 shows cases of hemorrhagic fever and abortion in cows. Blood was
collected in 5mL purple-top Vacutainer tubes (without anti-coagulant). Demographic
information of farmers such as address and complete identification of sampled animals
(age, sex, breed, clinical signs, status of RVFV vaccination, and breed) were also
collected. From the field, samples were transported to the Virology laboratory of Rwanda
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Agriculture Board immediately at Rubirizi station. Samples were then put into 2 mL
Eppendorf tubes and kept in -80oC and subsequently, samples were shipped to Louisiana
State University for additional analyses.

Figure 4.1. Clinical manifestations of cattle during RVF outbreak. A and B. Case of
hemorrhagic fever, C and D. Abortion cases. This picture also shows the risk of exposure
from animals to human population as the environment was contaminated by infected
tissues.
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4.2.2. Viral RNA extraction and cDNA synthesis
TRI Reagent® was added to each sample homogenate in DNA/RNA Shield™ in a
ratio of 3:1 after what RNA extracted was performed using Direct-zol

TM

MiniPrep Zymo

Research kit (Cat No. R2052) according to manufacture instructions. First-step total
cDNA synthesis was performed on RNA extracted from whole blood. 8μL RNA was added
to 1μL random hexamers and 1μL dNTPs and run on thermocycler at 65oC for 5min. After
that, to this 10μL was added another 10μL consisting of 2μL 10X RT Buffer, 4μL 25mM
MgCl2, 2µL 0.1m DTT, 1µL RNase OUT, 1µL Superscript III RT (Invitrogen kit, Cat No.
18080-051). The new 20μL was run on thermocycler at 25oC for 10min, 50oC for 50min,
and 80oC for 5min. 1µL of RNase H were added to collected reactions and put back on
thermocycler at 37oC for 20 min. A total of 21µL cDNA was collected and kept in -20oC
until ready to use.
4.2.3. DNA amplification
Samples were first tested for RVFV infection. RVFV was detected by conventional PCR
using

primers

targeting

conserved

90bp

region

of

L

segment

(Fwd

5’-

TGAAAATTCCTGAGACACATGG-3’ and Rev 5’- ACTTCCTTGCATCATCTGATG-3’)
(LaBeaud et al. 2011). 1 μL of total cDNA was added to the PCR mixture of Qiagen
HotStar Taq DNA polymerase kit (Cat. No. 203205) containing 2.5 µL 10X PCR Buffer,
0.75 µL 50mM MgCl2, 0.55 µL 10mM dNTP, and 0.1 µL Taq as well as primers (1µL 10μM
forward primer and 1 µL 10μM reverse primer) and 18.15 µL ddH2O. A total of this PCR
mixture was put on Applied Biosystems 2720 thermal cycler under these cycling
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parameters used were 95oC for 15 min; 30 cycles of 94oC for 30 sec, 50oC for 30 sec,
72oC for 1 min and 72oC for 10 min (LaBeaud et al. 2011).
The amplicons were stained by GelRed (Biotum, Cat No. 41003), run on 2% agarose
gel with 1X TAE buffer at 100V for 1 hour, and visualized with Bio View UV Light
transilluminator. After samples were tested for RVFV, cDNA of RVF negative samples
were pooled by 5-7 according to districts of origin and were tested for BUNV, BATV, and
NRIV using cycling parameters mentioned in Chap 2. Potential co-infection cases of
RVFV and these three Orthobunyaviruses were detected by testing RVF positive samples
for BUNV, BATV, and NRIV as well. Detection of the three Orthobunyaviruses was done
by targeting all the three segments S, M, and L for each virus by PCR. Primers and cycling
parameters used are shown in Chapter 2 (Table 2.3). As mentioned previously in Chapter
2, there was a good cross-reaction between our L primers of BUNV and NRIV but not
between M primers of BATV and NRIV. Thus, positivity of M primers was only required
for homologous amplification and diagnosis was confirmed as shown in Table 4.1.

Table 4.1. Diagnostic scheme of BUNV, BATV, and NRIV using M and L primers.
BUNV

BATV

NRIV

Conclusion

S

M

L

S

M

L

S

M

L

+

+

+

-

-

-

+

-

+

BUNV +

+

+

+

-

-

-

+

+

+

+

+

+

+

+

+

+

+

+

-

-

-

+

+

+

-

-

-

BUNV and NRIV
co-infection
BUNV, BATV, and
NRIV co-infection
BATV+

+

-

+

+

+

+

+

+

+

+

+

+

+

+

+

+

-

+

+

-

+

-

-

-

+

+

+
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BATV and NRIV
co-infection
BUNV and BATV
co-infection
NRIV+

4.3. Results
4.3.1. Epidemic timing
The outbreak started in Ngoma and Kirehe districts (Eastern province) in the end of
May and many cases were still reported in these two districts at the end of the outbreak
in the end of July. The spread continued in other parts of the country starting by other
districts of Eastern province (Kayonza, Gatsibo, Rwamagana). The Southern province
was also heavily affected followed by Northern province. Western province and Kigali city
were affected late and at low level (Figure 4.2 and Figure 4.3). Animal movements were
banned from mid-June to the end of July. Human cases were not documented except
death of two veterinary officers; Ngoma on June 11 and Kamonyi on July 3. The outbreak
transmission was stopped by massive vaccination campaigns of healthy and nonpregnant animals.

Figure 4.2. Administrative map of Rwanda depicting provinces and districts (NSRI 2019).
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Figure 4.3. Epidemic chronology of RVF outbreak.
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4.3.2. Rift Valley Fever prevalence
There were more cows sampled than goats, due to the economic and cultural
importance of cows. Over 97% of samples were female, with the exception of 4 male
calves included because their mothers had hemorrhagic fever symptoms and mothers
have died within the last 3 days (Table 4.2). Approximately 79.5% of samples came from
family farms compared to commercial farms. Cattle were identified as either exotic, local,
or crossed breed. Almost 65% of cows sample were classified as crossed breed.
However, the study was not designed to test for differences in positivity among breeds.
According to owners, none of the sampled animals were vaccinated for RVF. 30.3%
(56/185) samples were positive to Rift Valley Fever. Of those that were positive for RVFV,
26.7% manifested in hemorrhagic disease while 82% presented with abortion. All cases
of hemorrhagic disease were reported deceased 1 to 4 days after sample collection.
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Table 4.2. Sample categories and proportions of positive samples.
Samples categories

Total number of
RVF positive
samples collected samples

Overall prevalence
Species

185
157
28
181
4
147
38
16
102
39
157
15

56 (30.27%)
44 (28.02%)
12 (48.85%)
55 (30.38%)
1 (1/4)
41 (27.89%)
15 (39.47%)
6 (37.5%)
30 (29.41%)
8 (20.51%)
46 (29.29%)
15 (100%)

41
32
18
28
5
17
15
3
5
1
5
10
1
1
3

10 (24.39%)
7 (21.87%)
6 (33.33%)
12 (42.85%)
4 (4/5)
9 (52.94%)
4 (26.66%)
1 (1/1)
1 (1/1)
1 (1/1)
1 (1/3)

Cattle
Goats
Sex
Female
Male
Type of farm
Family
Commercial
Breeds (cattle)
Local
Crossed
Exotic
Clinical symptoms
Abortion
Hemorrhagic
fever
Geographic Eastern
Ngoma
distribution province Kirehe
Kayonza
Gatsibo
Rwamagana
Southern Ruhango
province Kamonyi
Muhanga
Nyanza
Gisagara
Northern Gakenke
province Gicumbi
Western Ngororero
province Rusizi
Kigali
Gasabo
city
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4.3.3. Identification of Orthobunyaviruses in Rift Valley Fever negative samples
Among the 129 RVF negative samples, 7 were positive to BUNV and/or BATV. Two
samples were exclusively positive to BUNV, two were exclusively positive to BATV, while
three were positive to all segments of both viruses. These 7 samples were either from
Southern (Nyanza, Ruhango, and Kamonyi districts) and Northern province (Gakenke
and Gicumbi districts). Figure 4.4 shows the visualization on 2% agarose gel of DNA
bands for amplified regions of BUNV and BATV S, M, L segments of these 7 samples.

Figure 4.4. Positive samples to BUNV and/or BATV and negative RVFV.
Nyan-61 and Kam-143: positive to BATV only; Gak-84 and Gic-120: positive to BUNV
only; Gic-127, Ruh-128, and Ruh-129: positive to both BUNV and BATV
Nyan= Nyanza; Gak=Gakenke; Gic=Gicumbi; Ruh=Ruhango; Kam=Kamonyi
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4.3.4. Potential co-infection of Rift Valley Fever virus and Orthobunyaviruses
Ten (10) Rift Valley Fever positive samples had evidence of Orthobunyavirus coinfection. However, based on the diagnostic scheme for our three viruses of interest, none
of them were decisively positive to either BUNV, BATV or NRIV. One sample was positive
for two segments of BUNV.
Although these results are not conclusive, they are indicative of potential co-infection
of multiple Bunyaviruses in Rwanda and potentially previously undetected reassortants.

Table 4.3. Potential co-infection of RVF and Orthobunyaviruses
Sample No
& District

Gatsibo102
Rwamagana106
Rwamagana108
Rwamagana109
Ruhango132
Kamonyi144
Ngoma160
Ngoma167
Kayonza195
Kayonza198

RVFV

BUNV

L

S

M

BATV
L

S

+

M
+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

L

NRIV
S
+

+

+

+

+

+

+

+

+

+

+
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+
+
+
+
+
+
+
+

L

RVF+, BUNV+/NRIV+
RVF+,
BUNV+/BATV+/NRIV+
RVF+,
BUNV+/BATV+/NRIV+
RVF+, BUNV+/NRIV+
RVF+,
BUNV+/BATV+/NRIV+
RVF+, BUNV+
RVF+, BUNV+/BATV+

+
+

M

Conclusion: potential
co-infection of RVFV
and either BUNV or/and
BATV or/and NRIV
RVF+, BATV+/NRIV+

RVF+, BATV+/NRIV+
RVF+, BATV+

4.4. Discussion
In this study, we identified RVFV as the causative agent of hemorrhagic fever and/or
abortion in over 30% of cases during the largest outbreak documented in Rwanda. The
outbreak highly affected the Eastern province of Rwanda, which was not surprising as it
has been shown to be the most suitable region for mosquito life cycles. This region is
characterized by multiple lakes, rice plantations, and the lowest altitude of the country
(<2,300m), low precipitation, and banana plantations in close proximity to households
(Demanou 2012). These ecological determinants, coupled with heat and humidity, make
this region very suitable for mosquito breeding. For example, a mosquito survey
conducted in 2011 showed that this region had the highest density of four of the most
One Health relevant mosquito species (in order of highest density to lowest): Culex spp,
Aedes spp, Coquilletidia spp, and Anopheles spp. Culex and Aedes are presumed
primary and secondary vectors of RVFV and have been shown to be competent for these
Orthobunyaviruses (Odhiambo et al. 2014). All districts of Eastern provinces were
affected except Bugesera and Nyagatare districts, which have undergone very systematic
vaccination campaigns in less than one year before the outbreak occurs. This
underscores the need for high coverage vaccination programs to preserve the herd health
of ruminants to RVFV.
In addition, we molecularly confirmed the presence of other Orthobunyaviruses, BUNV
and BATV. We show that these viruses, in a small number of cases, caused abortions in
ruminants, similar to RVFV. This suggests that these viruses are contributing to RVFVlike illnesses in Rwanda and may be present in neighboring countries. This is the first
time another Bunyavirus other than RVFV is reported in Rwanda and the second time
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BATV is identified in Africa by molecular technique. BATV mainly circulates in Europe
and Asia was isolated in Uganda in 1967 and only suspected in Sudan in 1988 based on
serological evidence (East African Research Institute 1967, Nashed, Olson, and el-Tigani
1993).
This study represented the second molecular confirmation of BATV in an acutely ill
vertebrate in Africa.
Importantly, this study demonstrated that cows could be co-infected with BATV and
BUNV. The provenance of NRIV is unknown but assumed to have occurred due to a coinfection with BUNV and BATV. This is largely assumed to have happened in the vector
(REFS). However, our study shows that this might have occurred in a cow.
Further, not only did we identify these viruses in Rwanda, but we demonstrate for the
first-time co-infection with RVFV and unidentified Orthobunyaviruses. Our study was not
sufficient to definitively identify these other Orthobunyaviruses, but this represents an
important future direction, as many known and unknown arboviruses continue to
cryptically circulate in Africa. In neighboring countries, other Orthobunyaviruses related
to BUNV circulate including Ilesha and Germiston viruses (Yandoko et al 2007). This
raises the question of whether novel reassortants could be occurring in the region.
This study reports the identification of BUNV and BATV in the following districts:
Gicumbi (BUNV infection and BUNV/BATV co-infection), Gakenke (BUNV infection),
Nyanza (BATV infection), Ruhango (BUNV/BATV co-infection), and Kamonyi (BATV
infection) (Figure 4.5). RVFV was spread throughout the entire country, with higher
density in the southeast of the country. The Orthobunyaviruses shared a similar
distribution with RVFV, though obviously with less density.
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Figure 4.5. Geographic distribution of RVF and Orthobunyaviruses cases.
Ortho: BUNV or BATV positive case, RVFV: RVFV positive case, RVFV+uOrtho: potential
co-infection between RVFV and BUNV and/or BATV and/or NRIV, mOrtho: BUNV and
BATV co-infection cases.
There is a general dearth of knowledge regarding the ecology of arbovirus
transmission in Rwanda. Environmental suitability studies on potential vectors and role of
environmental parameters should be conducted in order to understand transmission
dynamics and offer control solutions. The scope of this study was a detection of viral RNA
among acutely ill animals during an outbreak of RVFV-like illness. However, we speculate
that seroprevalence will be higher in the general cattle population, and perhaps in the
human population. Importantly, though RVFV was assumed ot be the causative agent of
disease in this unprecedented outbreak, there was a high proportion of samples negative
for all viruses tested here. The etiology of these cases could be due to any number of
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pathogens that share clinical manifestation, namely Brucellosis and anaplasmosis. These
are important issues warranting further research in the region.
Overall, we demonstrate that RVFV was responsible for only 30% of tested samples
with RVFV-like illness. We also show that BUNV and BATV co-circulate with RVFV and
are capable of producing acute illness in ruminants. Further, our data suggests that coinfections among Orthobunyaviruses and between Orthobunyaviruses and RVFV occur,
and that there may be other Orthobunyaviruses circulating in the region. Further work is
needed to describe the biodiversity of arboviruses in Rwanda, the ecology of such
(including vectors, thermal limits of transmission, reservoirs, etc.), and the possibility of
causing human disease.
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CHAPTER 5. GENERAL DISCUSSION AND CONCLUSIONS
5.1.

Introduction

Although many laboratory and some natural reassortment events have been observed
among members of the Bunyavirales order (Gentsch and Bishop 1976; Borucki et al.
1999; Bowen et al. 2001; Briese et al. 2006; Bodewes 2010; Aguilar et al. 2011, Briese,
Calisher, and Higgs 2013; Eiden, Vina-Rodriguez, El Mamy, Isselmou, Ziegler, Höper, et
al. 2014; Hontz et al. 2015), few comparative have been studies are conducted on
parental and progeny viruses resulting from the genome reassortments. In this study, we
compared in vitro and in vivo kinetics of Bunyamwera (BUNV), Batai (BATV), and Ngari
(NRIV) viruses, three viruses of One Health concern belonging to Orthobunyavirus genus,
Peribunyaviridae family in the Bunyavirales order (Bowen et al. 2001; , Gerrard et al.
2004; Briese et al. 2006; Maes et al. 2019). NRIV is a progeny virus of BUNV and BATV
(Bowen et al. 2001; Briese et al. 2006; Yandoko et al. 2007; Groseth, Weisend, and
Ebihara 2012). In vitro studies were conducted in Vero cells, one of the most commonly
used laboratory cell lines, and in vivo studies were conducted by infections in wildtype
C57BL/6 mice. In addition, this research project presents data collected from studies that
investigated the hypothesis that these three Orthobunyaviruses co-circulate and
contribute to the burden of disease in a Rift Valley Fever (RVF) endemic area, during the
RVFV outbreak of May-July 2018 in Rwanda. This hypothesis was based on evidence of
circulation of these viruses in neighboring countries (Kokernot et al. 1958; Nashed, Olson,
and el-Tigani 1993; Dutuze et al. 2018; Gerrard et al. 2004; Briese et al. 2006; Wertheim
2012; Otieno 2015), lack of consistent molecular confirmation of RVFV in acutely ill
animals, and the documented similarity of clinical manifestations among diseases caused
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by RVFV, BUNV, BATV, and NRIV (Nashed, Olson, and el-Tigani 1993; Elliott 1996;
Briese et al. 2006; Hollidge, Gonzalez-Scarano, and Soldan 2010; Ikegami 2011; Elliott
2013; Eiden, Vina-Rodriguez, El Mamy, Isselmou, Ziegler, Hoper, et al. 2014; Soldan and
González-Scarano 2014).
In this chapter we summarize the findings and provide general conclusions and future
perspectives as results from this study constitute a valuable baseline for deeper
characterization of these understudied viruses.
5.2. Summary of results
5.2.1. In vitro infection kinetics, in vivo infection kinetics, and ex vivo stability of BUNV,
BATV, and NRIV
We conducted in vitro studies which constitute a valuable tool for giving insight into
infection kinetics in natural hosts (Chapter 2). Through in vitro studies of BUNV, BATV,
and NRIV in Vero cells, we demonstrated that there was 1) similarity of plaque
morphology between BUNV and NRIV more than the other pairwise comparisons, 2)
stability of these three viruses in extracellular conditions at different inoculation doses up
to 30 dpi, and 3) a general lack in differences among the three viruses of growth kinetics
in Vero cells.
BUNV and NRIV plaques were found to be similarly heterogenous with a mixture of
small, medium, and large plaques, while BATV generally produced homogenously large
plaques. Studies have shown that isolates from different sized plaques of BUNV and
NRIV have different pathogenicity, as small BUNV plaques were more lethal in suckling
mice while larger NRIV plaques were more lethal (Odhiambo et al. 2014). We speculate
that the ability of these viruses to produce these small plaques with differential infectivity
might account for the observed higher pathogenesis of BUNV and NRIV compared to
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BATV. This avenue of research warrants further investigation to determine if within host
variants (i.e. plaque-size associated phenotypes) do actually cause higher disease.
BUNV, BATV, and NRIV were all found to be stable and infectious in extracellular
conditions for up to 30 days. This suggests a potential of these viruses to be directly
transmitted via environmental fomites, should they come into contact with mucous
membranes or open wounds. Other members of the Bunyavirales order have been found
to be directly transmitted in farms where abortive tissues, blood secretions (in cases of
hemorrhagic fever), and various equipment play a significant role in transmission
especially during outbreaks (Valero 2017, Hartman 2017, Stavropoulou and Troillet 2018,
Pshenichnaya and Nenadskaya 2015). The environmental stability of these viruses in
field conditions relevant to the region (such as desiccation, humidity differences, and
sunlight exposure) should be tested to provide more information regarding the
transmissibility of environmentally stable viruses. The prolonged stability of these viruses
led us to investigate the efficacy of inactivation of laboratory detergents. We report that
1%Triton-X-100 after one-hour incubation could inactivate the three viruses.
Comparative in vivo studies (Chapter 4) were conducted in C57Bl/6 mice, to determine
if these mice were a good model for infection and/or disease. We compared the viremia
status, antibody production, and cross-neutralization of antibodies following infection.
Viremia results showed that none of the BUNV or BATV infected mice were viremic, and
only 1/5 NRIV infected mice showed what looked like viremia (higher viral output than
initial input), though virus was detected for a much longer period of time in the NRIV
infected mice than the other two groups. While these mice do not appear to be good
models for infection, these results are suggestive of a potential lower virulence of BUNV
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and BATV compared to NRIV, which has been observed in human populations (Nashed,
Olson, and el-Tigani 1993; Gerrard et al. 2004; Briese et al. 2006).
There was at least some level of cross-neutralization among all pairs of the three
viruses. BUNV and BATV had already been shown to cross-neutralize each other as they
belong to the same serogroup (Bunyamwera serogroup) (Hunt and Calisher 1979).
However, ours is the first study of cross-neutralization of NRIV, and the first study to
compare across both parental viruses and the NRIV progeny. We report a strong
neutralization of BATV by NRIV, which was expected as these two viruses share M
segment which encodes glycoproteins, which serve as triggers for neutralizing antibody
production (Bowen et al. 2001; Gerrard et al. 2004; Groseth, Weisend, and Ebihara 2012).
However, serum from BATV exposed mice did not neutralize NRIV and BUNV well, nor
itself. The low level of BATV homologous neutralization is likely indicative of low antibody
production by the strain of the mouse strain used in our experiment (C57BL/6) as they
quickly cleared the virus (Figure 3.6.A). The cross-neutralization of these viruses is
beneficial for exposed individuals living in areas where these viruses co-circulate as one
infection could provide protection for future infections of all the three viruses. Additionally,
given that neutralizing antibodies are crucial for vaccine-mediated protection against viral
diseases (Burton 2002), existence of cross-neutralization may provide the give the
possibility of developing common vaccine, though there may be different efficacy between
viruses. We speculate that cross-neutralization will likely confound serological diagnostic
development and could be a reason why BATV is less reported in Africa.
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5.2.2. Identification of Orthobunyaviruses in Rwanda
The general status of Bunyaviruses and arboviruses in general circulating in
Rwanda is not well characterized. The only Bunyavirus which was known to circulate in
Rwanda before our study was Rift Valley Fever Virus and only with evidence of circulation
since 2011 (Rwanda Agriculture Board 2013). In Chapter 4 of our study, we provide
evidence that BUNV and BATV both circulate in Rwanda contributing to RVF-like disease.
In addition, we could not rule out the presence of NRIV as co-infection with BUNV and
BATV may mask the additional presence of NRIV. In addition to these confirmed cases,
we also report cases of non-conclusive combinations of genome segments of
Orthobunyaviruses, which indicates the presence of these viruses and potentially new
reassortment events. Further characterization of these genomes should be made in an
effort to determine if they are known virus sequences or unknown serogroup members.
The scarcity of molecular confirmation compared to clinical diagnosis in outbreak
settings can lead to misdiagnosis. In the case of these bunyavirus infections (and more
generally, arbovirus infections), disease is often characterized by non-specific clinical
signs or by signs that are attributed to a known agent, such as RVFV.
RVFV, for example, was confirmed for the first time in 2011 in Rwanda after being
suspected due to uncommonly high incidence of abortions concentrated in one part of the
country, following the known seasonality of RVFV from other regions (Rwanda Agriculture
Board 2013; Umuhoza et al. 2017). Given that many cases of RVFV infections are
characterized by non-specific mild illnesses (Easterday 1965; Ikegami 2011), it is possible
that it was already circulating long before 2011 in less intense or even asymptomatic
forms. This is very important as education and affordability to veterinary services play
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important role in requesting veterinarian services in rural areas of Rwanda. Most farmers
don’t usually notify veterinarians for mild forms of diseases, which means that
transmission may go unabated.
In May-July 2018, at the time of our study, an unprecedented outbreak of RVFV-like
illness occurred in Rwanda (OIE 2018). The high transmission of RVFV was the
consequence of exceptionally heavy rain in March and April causing flooding events. This
was commonly seen in other countries in East Africa (Kenya, Uganda, and Tanzania)
(OIE 2018, WHO 2018).
This outbreak allowed us to test our hypothesis that these Orthobunyaviruses may
contribute to RVFV-like illness in real-time. We were able to conclusively detect
conclusively cases of BUNV (2/127), BATV (2/127), and BUNV/BATV co-infections
(3/127) in RVFV negative samples. Further, there were non-conclusive combinations of
RNA genome segments of BUNV, BATV, and NRIV by PCR in RVFV positive samples
(10/56). While the RVFV cases were predominantly reported in Eastern provinces, all
Orthobunyaviruses conclusive cases were were found in Northern and Southern
provinces (map, Figure 4.2) and non-conclusive cases found in Southern and Eastern
provinces. Although the overall reported prevalence of Orthobunyaviruses was low, their
presence itself is indicative of emergence of subsequent surveillance considerations; and
the geographic differences in cases may indicate an ecological niche divergence which
could be used for targeted surveillance for Orthobunyaviruses in future.In addition, given
these ecological differences, further studies are needed to determine the vector ranges
of these viruses, as mosquito biodiversity, populations, and abundance differ across
Rwanda. Further, the actual prevalence of these viruses in Rwanda could be greater than
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what we observed due to the asymptomatic aspect of bunyaviral diseases (Elliott 1996;
Elliott 2013; Soldan and González-Scarano 2014).
In the human population, no evidence of RVFV has been shown in Rwanda. But this
is highly suspected due the proximity between humans and animals, especially in rural
areas of Rwanda. Fever which is the most common manifestation of Bunyaviral disease
in its mild form, is usually diagnosed as malaria without confirmatory laboratory testing
(Amexo et al. 2004). The only systematically studied arbovirus in the human population
is yellow fever and was reported at very low seroprevalence (0.2%, 2/1284 participants)
(Demanou 2011). The same assessment study reported a very small population of Aedes
spp mosquitoes (190 out of 1971 mosquito collected all over the country (Demanou
2011). Without molecular confirmation, it may be that a proportion of human febrile
illnesses in Rwanda is attributable to one of these or other Orthobunyaviruses, and
serological surveys could ascertain the exposure rate in human populations as well.
The non-conclusive combinations of genome segments could be indicative of possible
reassortment events between these viruses or the presence of other Orthobunyaviruses
known to circulate in the region such Ilesha, Germiston, and Shokwe (Yandoko et al.
2007). In addition, the non-conclusive results could also indicate the presence of
uncharacterized Orthobunyavirus species or reassortment progeny. Further studies in the
region would allow for the identification and study of the relatively neglected group of
Orthobunyaviruses currently circulating in the region.
5.3.

Conclusions and future perspectives

Human-animal disease transmission in Rwanda is facilitated by the fact that livestock
animals are found in close proximity to many households, especially in rural areas of
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Rwanda. This interaction is also enhanced by some Rwandan Government programs for
alleviation of poverty and malnutrition such as “Girinka” (One cow per family) which
promotes the owning of cows in poor families to increase access to animal proteins at low
cost (Rwanda Government Board 2018). This proximity increases the risk of zoonotic
disease transmission while simultaneously providing a benefit to the family.
This work significantly contributes to the increase in knowledge available on
BUNV, BATV, and NRIV as it characterizes the comparative in vitro and in vivo infections
of these viruses and contributes to identification of these viruses in new geographic areas.
Based on the findings of our study, we recommend enhanced laboratory inactivation
practices when handling these viruses due to their stability in extracellular medium, and
we further confirm that the use of 1% Triton-X-100 successfully inactivates these viruses.
We further suggest that, surveillance efforts in Rwanda and other East African countries
should allow for pathogen discovery whenever possible, though we recognize the
considerable challenges that may be faced.
Finally, we highlight the need for more investigation of these and other undercharacterized arboviruses. In infection kinetics, more research is needed to determine the
mechanisms for observed higher virulence of NRIV compared to BATV and BUNV. For
the transmission dynamics of these viruses in Rwanda, more investigation is needed on
the comparative ecologies of these viruses, including the host ranges (humans, livestock
species, and wildlife), the role of hosts in epidemiology (reservoirs, dead-end hosts, and
amplification hosts), identification of competent vectors, and the identification of other
Bunyaviruses circulating in the region.
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This problem exemplifies the concept of One Health where animal health – here,
because of the direct benefit of the animal to the issue of child-growth stunting, and the
increase risk of zoonotic transmission – is a direct influencer of human health. Further, as
we have shown the geographical distribution of these viruses is different, the
environmental factors associated with these geographies likely contributes to the risk of
transmission (as with flooding events and increased RVFV transmission). Our study
points to the necessity for a One Health approach to disease surveillance and mitigation,
especially in developing nations.
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B.2 AUC of BATV in standard cell culture conditions (10%FBS)
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B.3 AUC of NRIV in standard cell culture conditions (10%FBS)
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B.4 AUC of BUNV in sub-standard cell culture conditions (2%FBS)
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B.5 AUC of BATV in sub-standard cell culture conditions (2%FBS)
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B.6 AUC of NRIV in sub-standard cell culture conditions (2%FBS)
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